 
[ADDRESS_8082]  | Toronto, Ontario  M5S 2E , Canada | biossil.co  
 
14 February 2025  
Re: Cover Letter for ClinicalTrials.gov [STUDY_ID_REMOVED]  
 
This Cover Letter accompanies  the final  Protocol (Amendment 3 ; 01 April 2019 ) for th e 
completed trial, [STUDY_ID_REMOVED] .  
 
Sincerely,  
 
 
 
Debora Manning, MPH  
Head of Regulatory  
Biossil Inc . 
[EMAIL_165]  
 
 
 
Docusign Envelope ID: 03C8F23D-76C1-45C5-A4A6-36ACFAD01C94

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 3Document Version Date Summary of Changes 
-Clarified that Readiness -for-Discharge 
assessments will occur at regular pre -defined 
intervals during the day time hours (6am to 
10pm) and removed the requirement for routine 
assessments during the night -time hours (10pm 
to 6am). Indicated that an ad hoc assessment 
would be required if a subject is considered to 
have achieved readiness -for-discharge during the 
night -time hours ;
-Extended the period of time a subject is able to 
screen into the Open Label Extension Study  
(B5201003) to [ADDRESS_8083] visit in 
B5201002;
-Removed the option to sign consent for the 
Open Label Extension Study  (B5201003) at 
hospi[INVESTIGATOR_8798]  B5201002
;
-Added eligibility  criteri onexclud ingsubjects 
currentl y receiving, or expected to receive, 
transdermal analgesics
;
-Added eligibility  criterion excluding subjects 
who were previousl y randomized into the current 
study ;
-Clarified that the adjudication committees will 
only evaluate adverse events occurring from the 
time of the subject’s first dose of study  drug to 
thesubject’s last study  visit ;
-Removed requirement to completely  shroud the 
studydrug IV infusion line with tinted tubing 
covers ;
-Updated information regarding the  
compatibility  of rivipansel with other IV fluids ;
-Restructured 
the c oncomitant treatment section 
(Section 5.8) to include newly  added prohibited 
medications (transdermal analgesics and 
systemic steroids [when used exclusively  for 
treatment of uncomplicated VOC] ) as well as to
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 8Document Version Date Summary of Changes 
Plans (SAP), and to streamline and simplify the 
analysismethods for subgroups and exploratory  
endpoints.- Clarif iedin Section 9.2.[ADDRESS_8084] of country  health authorities and, institutional review boards (I RBs)/ethics 
committees (
ECs).  
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 12SCHEDULE OF ACTIVITIES
The Schedule of Activities table provides an overview of the protocol visits and procedures.  Refer to Study  Procedures and 
Assessments sections of the protocol for detailed information on each pro cedure and assessment required for compliance with the 
protocol .
The investigator may  schedule visits (unplanned visits ) inaddition to those listed on the schedule of activities, in order to conduct 
evaluations or assessments required to protect the well being of the subject .
Table 1. Schedule of Activities
Study 
ProcedurePre-VOC/
Study 
Entry 
ScreeningMonthly 
Contact[CONTACT_8852]/
Treat -
m
ent -
Ready 
ScreeningDouble- Blind Treatment Post-
Treatment 
Daily 
Assess-
mentsDischarge Post-Discharge 
Daily 
AssessmentsPost-Discharge 
Follow -Up
Phone
CallxPost-
Discharge 
Follow -Up 
VisitxLoading 
DoseFirst 
24
HourspDaily 
Assess-
mentsEnd of 
Treat -me
ntv
Visit Number Visit 1: During Hospi[INVESTIGATOR_059] [ADDRESS_8085]-
Disch
arge 
Day 
7±3Post-
Disch
arge 
Day 
21±5Post-
Discharge 
Day 35 ±5
Informed 
consent/
assent(X)n(X)n
Enter subject into 
electronic system 
to document 
entry into 
Screening period(X) X
Affirmation of 
informed consent(X)n
Demographics X
Medical History X
SCD History X
Complete 
Physical 
ExaminationX
Targeted 
Physical 
ExaminationXsXsX X
Height, weight X
Vital SignsaX XttXtXtX
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 13Study 
ProcedurePre-VOC/
Study 
Entry 
ScreeningMonthly 
Contact[CONTACT_8852]/
Treat -
ment -
Ready 
ScreeningDouble- Blind Treatment Post-
Treatment 
Daily 
Assess-
mentsDischarge Post-Discharge 
Daily 
AssessmentsPost-Discharge 
Follow -Up
Phone
CallxPost-
Discharge 
Follow -Up 
VisitxLoading 
DoseFirst 
24
HourspDaily 
Assess-
mentsEnd of 
Treat -me
ntv
Visit Number Visit 1: During Hospi[INVESTIGATOR_059] [ADDRESS_8086]-
Disch
arge 
Day 
7±3Post-
Disch
arge 
Day 
21±5Post-
Discharge 
Day 35 ±5
Clinical 
LaboratoriesbX X X
UrinalysiscX X X
Pregnancy TestdX X X
Contraception 
checkX X X X
Hemoglobin 
Electrophoresisg(X)
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 14Study 
ProcedurePre-VOC/
Study 
Entry 
ScreeningMonthly 
Contact[CONTACT_8852]/
Treat -
ment -
Ready 
ScreeningDouble- Blind Treatment Post-
Treatment 
Daily 
Assess-
mentsDischarge Post-Discharge 
Daily 
AssessmentsPost-Discharge 
Follow -Up
Phone
CallxPost-
Discharge 
Follow -Up 
VisitxLoading 
DoseFirst 
24
HourspDaily 
Assess-
mentsEnd of 
Treat -me
ntv
Visit Number Visit 1: During Hospi[INVESTIGATOR_059] [ADDRESS_8087]-
Disch
arge 
Day 
7±3Post-
Disch
arge 
Day 
21±5Post-
Discharge 
Day 35 ±5
Inclusion/
Exclusion 
criteriaX
Randomization X
Study Drug 
AdministrationjX X X
Readiness -for-
Discharge 
Criteria )kX X X X X
Date and Time of 
DischargeX
Telephone 
Contact(X) X X
Adverse Events (X) (X) (X) X X XtX X X X X X
Prior/Concomita
nt MedicationsX X X XtX X X X X X
Parenteral 
Opi[INVESTIGATOR_8799] X X XtX X X
Prior/Concomita
nt Non -drug 
Treatments/
ProceduresX X X X X X X X X X
Informed 
consent/assent 
for Open -Label 
Extension Studym(X)
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8088] OF TABLES ...................................................................................................................21
APPENDI CES .........................................................................................................................22
1. INTRODUCTION ...............................................................................................................23
1.1. Mechanism of Action/I ndication .............................................................................25
1.2. Background and Rationale
......................................................................................25
1.2.1. Drug Development Rationale
.....................................................................25
1.2.2. Pre -Clinical Development of Rivipansel ....................................................26
1.2.3. Clinical Experience with Rivipansel
..........................................................26
1.2.4. Study  Rationale ...........................................................................................28
1.2.5. Dose Rationale ............................................................................................28
1.3. Summa ry of Benefit Risk Assessment ....................................................................29
2. STUDY OBJECTIVES AND ENDPOINTS .......................................................................30
2.1. Objectives ................................................................................................................30
2.1.1. Primary  Objective .......................................................................................30
2.1.2. Secondary  Objective ...................................................................................30
2.2. Endpoints .................................................................................................................30
2.2.1. Efficacy  Endpoints ......................................................................................30
[IP_ADDRESS]. Primary ................................ ................................ ...................... 30
[IP_ADDRESS]. Secondary ..................................................................................[ADDRESS_8089] SEL ECTION ................................ ................................ ................................ ......37
4.1. I nclusion Criteria .....................................................................................................37
4.2. Exc lusion Criteria ....................................................................................................38
4.3. L ife Sty le Guidelines ...............................................................................................41
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8090] Compliance .................................................................................................44
5.4. Dru g Supplies ..........................................................................................................44
5.4.1. Dosage Form(s) and Packaging ..................................................................44
5.4.2. Preparation and Dispensing ........................................................................45
5.5. Administration .........................................................................................................46
5.6. Drug Storage ...........................................................................................................47
5.7. Drug 
Accountability ................................................................................................48
5.8. Concomitant Treatment(s) .......................................................................................48
5.8.1. Prohibited Prior to Study  Entry ..................................................................48
5.8.2. Prohibited During the Study .......................................................................48
5.8.3. Permitted During the Study ........................................................................48
5.8.4. Pain Management .......................................................................................49
5.8.5. Transfusion .................................................................................................50
6. STUDY PROCEDURES
.....................................................................................................50
6.1. Screeni ng.................................................................................................................52
6.1.1. Pre -VOC/Study  Entry  Screening ................................................................52
[IP_ADDRESS]. Consent of Subjects
...................................................................52
[IP_ADDRESS]. Monthly  Telephone Contacts
....................................................52
6.1.2. VOC/Treatment -Ready  Screening ..............................................................52
[IP_ADDRESS]. Visit 1, VOC/Treatment -Read y Screening ................................52
6.2. Study  Period ............................................................................................................55
6.2.1. Visit 1, Day  1
–Loading Dose ...................................................................55
6.2.2. Visit 1, Day  1
–First 24 Hours After Loading Dose ................................ ..56
6.2.3. Visit 1, Day  2through Day  8 (or End of Treatment)................................ ..[ADDRESS_8091] -Discha rge Daily  Assessments .........................................................................60
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8092] Findings ..........................................................................................84
8.6. Serious Adverse Events ...........................................................................................84
8.6.1. Protocol
-Specified Serious Adverse Events ...............................................85
8.6.2. Potential Cases of Drug -
Induced Liver Injury............................................85
8.7. Hospi[INVESTIGATOR_059] ........................................................................................................86
8.8. Severity  Assessment ................................................................................................87
8.9. Causality  Assessment ..............................................................................................88
8.10. Exposure During Pregnancy ................................ ................................ .................. 88
8.11. Occupational Exposure .........................................................................................89
8.12. Withdrawal Due to Adverse Events (See Also the Section on Subject 
Withdrawal)
...............................................................................................................90
8.13. Eliciting Adverse Event I nformation ....................................................................90
8.14. Reporting Requirements ........................................................................................90
8.14.1. Serious Adverse Event Reporting Requirements
.....................................91
8.14.2. Non
-Serious Adverse Event Reporting Requirements .............................91
8.14.3. Sponsor’s Reporting Requirements to Regulatory  Authorities ................91
9. DATA ANALYSI S/STA TISTICAL  METHODS ................................ ............................... 92
9.1. Sample Size Determination .....................................................................................92
9.2. Efficacy  Anal ysis....................................................................................................93
9.2.1. Analy sis of Primary  Endpoint ....................................................................94
9.2.2. Analy sis of Key  Secondary  Endpoints .......................................................95
9.2.4. Analy sis of Other Secondary  Endpoints .....................................................96
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8093] KEEPI[INVESTIGATOR_1645] .............................................................99
11.1. Case Report Forms/Electronic Data Record .........................................................[ADDRESS_8094] (IRB)/Ethics Committee (EC) .................................[ADDRESS_8095] OF TABLES
Table 1. Schedule of Activities ...........................................................................................12
Table 2. Sample Dosing Schedule (example of acceptable dosing schedule) ....................47
Table 3. Clinical L aboratory  Evaluations –Local Laboratory ...........................................72
Table 4. Triggered 
Requirements .......................................................................................72
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 22Table 7. Total Blood Volume in Adults ( ≥ 18 year of age) ...............................................80
Table 8. Total Blood Volume in Pediatrics 12 -
17years of age ..........................................80
Table 9. Total Blood Volume in Pediatrics 6 -
11years of age ............................................81
APPENDICES
Appendix 1. Estimated Glomerular Filtration Rate (eGFR) Calculations .............................109
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 231.INTRODUCTION
Sickle cell disease (SCD) is one of the most prevalent genetic disorders in the [LOCATION_002] 
(US), affecting approximately 100,000 people .1It is a chronic condition with substantial 
morbidity  and mortality , and is responsible for more than 75,000 hospi[INVESTIGATOR_8800] y ear in 
the US with an average stay  of 6.1 days
.2Both children and adults are affected, and greater 
mortality  is seen in those with more severe disease. 
SCD refers to a group of autosomal recessive inherite d disorders of the β -globin gene.  A 
single nucleotide substitution results in the presence of valine instead of glutamic acid in the 
β-globin chain.  The resulting poly merization of Hemoglobin S (Hb S) when deoxy genated is 
the primary  indispensable event in the molecular pathogenesis of SCD .3Individuals 
homozy gous for Hb S have sickle cell anemia (SCD
-SS).  Those who are compound (double) 
heterozy gotes have 1 copy  of Hb S and 1 copy of either Hb C (SCD -SC), Hb β+-thalassemia 
(SCD -Sβ+-thal), or Hb β0-thalassemia (SCD -Sβ0-thal).[ADDRESS_8096] notable is vaso -occlusive crisis 
(VOC), an e xtremely  painful and serious consequence of SCD, presumably  resulting from 
acute ischemic tissue injury . 
Over the course of a year, about 60% of patients with SCD -SS will have at least [ADDRESS_8097] majority  of hospi[INVESTIGATOR_602] (>90%), and result in significant morbidity , mortality , 
and interruption of dail y functioning.  Other problems include ischemic and hemorrhagic 
stroke, acute chest s yndrome (ACS) , splenic sequestration, dact ylitis, osteonecrosis, 
priapi[INVESTIGATOR_8801], leg ulcers, and nephropath y.3,6,7,8Most SCD -related deaths occur during acute 
VOC, and are due to ACS or stroke .9Patients can become s ymptomatic with p ain, infection, 
or splenic sequestration as earl y as 6 months of age; thus, VOCs are an important cause of 
morbidity  throughout life, resulting in disruption to the individual’s education, psy chosocial 
development, and employ ment as well as causing severe pain, hospi[INVESTIGATOR_059], and premature 
death.
Current medical management of SCD includes use of h ydrox yurea, which is used to increase 
fetal hemoglobin (Hb F) concentration and reduce the number of pain crises.  Treatment of 
acute VOC includes mainly  support ive measures such as opi[INVESTIGATOR_2467], hy dration, 
oxygen, and transfusion.  There is no mechanism -based treatment currently available, so this 
remains an unmet medical need.  Most patients attempt pain management at home, and seek 
medical care onl y when t his fails.  Therefore, the majority of painful epi[INVESTIGATOR_8802] .10
The etiology  of VOC involves dual mechanisms: a mechanical component, by  [CONTACT_8853] (RBCs) become caught in the post- capi[INVESTIGATOR_8803], and an 
associated inflammatory  response in which white blood cells ( WBCs
)adhere to the 
endothelium.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 24The underl ying pathogenesis of R ed Blood Cel l (RBC) S ickling is the deoxy genation of Hb 
S, which results in poly merization of the Hb, distortion of the RBC, and loss of deformabilit y 
of the cell .11These “sickled” RBCs are a primary  component of the occlusive process and 
cause vascular injury  through interactions with endothelial cells .6
The other primary  component is adhesive: stickiness of the cells which causes cell aggregates 
of WBC -RBC, WBC -WBC, and WBC -platelet to form.  This adhesion is selectin- mediated 
and contributes to the VOC process.  Cell aggregates block the vasculature a nd create a trap 
for the sickled RBCs, resulting in obstruction of blood flow4,[ADDRESS_8098] -capi[INVESTIGATOR_8803], local tissue hy poxia, and further tissue inflammation, 
resulting in more deox ygenation and sickling of RBCs, and propagation of the occlusion, 
sometimes called secondary  recruitment of sickled cells and occlud ed vessels .3Diapedesis 
(leukocy te migration into the tissues) and sickle- related microvascular occlusion also take 
place in postcapi[INVESTIGATOR_8803].   Pain is the result of initial and ongoing occlusion and 
ischemia
,8which results in higher mortality  in patients with the SCD -SS genoty pe, compare d 
toother genoty pes.9
Of note is that soluble E -
selectin, vascular cell adhesion molecules (VCAM)- 1, and 
intracellular adhesion molecules (ICAM) -[ADDRESS_8099] kinetics that allow cell adhesion to proceed under the shear forces of 
blood flow .19P-selectin is located on platelets and is also pre -formed and stored in 
Weibel -Palade bodies within the endothelial cells.  I t is a “first responder ” and is expressed at 
the endothelial cell surface within 30 minutes of an acute inflammatory  response .20
E-selectin is not pre -formed and stored, but requires de novo protein sy nthesis and is 
expressed on the endothelium 3 to 5hours after activation .21Both of these selectins are 
responsible for the earl y recognition and adhesion of leukocy tes to the vascular endothelium.   
L-selectin is located on a subset of leukocy tes and participates in rolling and adhesion and 
plays a major role in homing to the ly mph nodes.17
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 25The natural ligands for the selectins are carboh ydrate structures of the sial ylated Lewis 
antigens present on scaffolds of gl ycoproteins and gl ycolipid s (eg, PSGL -1, ESL -1, 
MAdCAM -1).  Following initial selectin- mediated recognition and rolling, the leukocy tes 
activate a second phase of adhesion while in close contact [CONTACT_8854].  As these events mostl y occur in a stepwise fashion, the selectins have 
been viewed as a target for upstream inhibition of the inflammatory  response.  By  [CONTACT_8855], and thereb y decreasing or preventing stickiness of 
RBC/WBC/endothelial cells in SCD, the pathophysiologic process of VOC may  be 
interrupted and/or prevented.  Damage caused b y these infiltrating cells in an inflammatory  
response is therefore prevented and blood flow may  be improved.
Inhibition of E -, P-, and L -selectins, a pan -selectin inhibi tion approach, offers potential 
promise as a useful therapeutic option. 
Data in the literature support a key  role for the selectins in VOC.  In particular, Turhan et al 
(2002) have shown that E -selectin and P -selectin are key  to the vaso- occlusion in a mouse 
model with the sickle genoty pe.[ADDRESS_8100] an 
important role in treatment of VOC.
  In addition, Embury  et al (2004) have shown the 
importance of P -selectin in contributing to microcirculatory  abnormalities.22  Kato et al 
(2005) have shown that increased soluble E -selectin levels in patients were associated with 
increased mortality  over a 4 -year period.14
GMI -
1070 ( rivipansel ) is a pan- selectin antagonist, a compound found to inhibit selectin 
binding in vitro and to inhibit selectin-mediated effects in vivo.  Selectin binding is a key 
early step in the inflammatory process leading to leukocyte adhesion and recruitment to 
inflamed tissue.  Selectin binding has been shown to be involved in most –if not all –disease 
processes that involve inflammation.  There are no other known approved therapeutic agents 
in this class.
This study  is designed to evaluate the efficacy  and safet y of rivipansel as treatment for VOC 
in hospi[INVESTIGATOR_8804]. 
1.1. Mechanism of Action/ Indication
Rivipansel is being developed as a pan -selectin antagonist for the treatment of V OCin 
subjects with SCD (including SCD-S S, SCD -SC, SCD -Sβ+-thalassemia, and 
SCD -Sβ0-thalassemia). 
1.2.Background and Rationale
1.2.1. Drug Development Rationale
Both P
-selectin and E-selectin are responsible for the earl y recognition and adhesion of 
leukocy tes to the vascular endothelium.   L-selectin is located on a subset of leukocy tes and 
participates in rolling and adhesion and play s a major role in homing to the ly mph nodes.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 26By [CONTACT_8856], and thereb y decreasing or preventing stickiness of 
RBC/WBC/endothelial cells in SCD, the pathophysiologic process of VOC may  be 
interrupted and/or prevented.   Damage caused b y these infiltrating cells in an inflammatory  
response is therefore prevented and blood flow may  be improved.
Rivipansel is a pan
-selectin antagonist developed at Gly coMim etics that inhibits selectin 
binding in vitro as well as selectin -mediated effects in vivo .  Inhibition of selectins offers 
potential promise as a useful therapeutic option for patients with SCD. Rivipansel has potent 
anti-inflammatory  effects in a number of animal models, including the sickle cell mouse, in 
which it has been shown to normalize blood flow, reduce blood cell aggregation, and to 
improve survival in a model of VOC.   In addition, the Phase 2 study  (GMI -
1070- 201) data 
have shown that such effec ts in SCD patients 
have led to a reduction in the length and 
intensity  of SCD pain crises.  Treatment of VOC with mechanism-based therapi[INVESTIGATOR_8805].  Both pediatric and 
adult patients w ould be expected to benefit substantially  from a therap y that could treat VOC 
and therefore measurabl y reduce the associated suffering and adverse clinical outcomes.
1.2.2. Pre-Clinical Development of Rivipansel
For information on nonclinical pharmacology , pharmacokinetics and product metabolism in 
animals, and toxicology  studies, p lease refer to the I nvestigator’s Brochure .
1.2.3.
Clinical Experience with Rivipansel
Clinical information is available from three completed Phase [ADDRESS_8101] of rivipansel on corrected QT
interval (QTc).
GlycoMimetic Studies  
In the first Phase 1 study  (GMI -1070- 101), healthy volunteer subjects received single 
intravenous ( IV)
doses of 2, 5, 10, 20, or 40 mg/kg rivipansel or placebo.   In the second 
Phase 1 study  (GMI -1070 -102), health y volunteer subjects received multiple IV doses of 
5,10, or 20 mg/kg rivipansel or placebo every  8hours for a total of 13 doses.   An additional 
group of subjects received a loading dose of 40 mg/kg, followed b y multiple doses of 
20mg/kg 
rivipansel every  8hours for a total of 6 doses.  These studies evaluated a total of 
72healthy  adult subjects (54 active, 18 placebo).
Pharmacokinetic (PK) data are available from the sestudies in healthy  volunteers.  Mean 
values for C max, area under the curve ( AUC )(0-t), and AUC (inf) increased in a dose -proportional 
manner, providing evidence of li
near pharmacokinetics.   After a single 20minute infusion of 
20mg/kg, the mean standard deviation C max was 256 43.7 mg/L.   The time of peak 
concentrations corresponds to the time of the end of infusion and the collection of the first 
blood sample for determination of GMI -1070.  The volume of distribution was consistent 
across dose levels, 0.130 to 0.181 L/kg.  Clearance was consistent across dose levels 
(0.211 to 0.284 mL/min/kg) and the mean elimination half -life (t ½) ranged from 6.67 hours to 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 277.41 hours.   Urine collection after the multiple dose administration showed a minimum of 
89% of the dose was recovered intact in the urine, and CL r was less than filtration clearance, 
consistent with tubular reabsorption. 
The third Phase 1 study  (GMI -1070- 103) w as an open -label stud y of IV rivipansel in 15 adult 
subjects with stable SCD who received a 20 mg/kg loading dose of IV rivipansel , followed 
10hours later b y a 10 mg/kg dose of IV rivipansel .  The pharmacokinetics were observed to 
be consistent with those in the health y volunteers.
In these three Phase 1 studies there 
were no clinically  significant electrocardiogram (ECG) or 
physical exam ination findings.  With one exception, all adverse events in subjects receiving 
rivipansel were Grades 1 or 2.  Severe s ymptomatic anemia (Grade 4) that occurred in 
1subject with stable SCD was considered to be remotely  related to the study  medication, and 
resolved with therap y.  
No serious adverse events were reported in these studies.
A randomized, placebo -controlled Pha se 2trial (GMI -1070- 201), evaluating the efficacy , 
safet y, and pharmacokinetics of multiple I V doses of rivipansel in 76 subjects 12 to 60 years 
of age who were 
hospi[INVESTIGATOR_8806].  This study  included two 
dosing schedules; t he first cohort received 20 mg/kg loading dose, then 10 mg/kg every  
12hours for up to 7 days, (maximum 15 doses) and the second cohort received 40 mg/kg 
loading dose, then 20 mg/kg every 12hours for up to 7days, (maximum 15 doses).
In the phase [ADDRESS_8102] sustained 
reduction in VAS pain score.   Mean use of opi[INVESTIGATOR_8807].
Total treatment -
emergent adverse event (TEAE) rates were comparable across groups.   
Serious Adverse Events (SAE) and those SAEs “related to treatment” were also comparable 
across groups. Eleven (11 , 14.4% ) subjects discontinued study  drug treatment due to adverse 
events (8 [10.5%] subjects inthe active group, and 3 [ 3.9%] subjects in the placebo group ) . 
No subjects discontinued participation in the study due to adverse events. A total of 
28serious adverse events (SAEs) were reported, encompassing 29 event terms across 
23 subjects.  A 30% SAE rate was seen in both active and placebo groups. The most 
common SAE in both treatment groups was re -hospi[INVESTIGATOR_8808]. One (1) SAE of 
acute generalized exanthematous pustulosis (AGEP) rash was seen in a subject who received 
the high dose; other less severe rash events were distributed across treated and plac ebo 
groups.  No subjects died.
Of note, the drug product formulation that will be used in this study  is a 30 mg/mL  solution 
for injection in which the concentration is 30 mg/mL  based on the active moiety  of 
rivipansel. The drug product used in the Phase 1 and Phase 2 studies described previously  
(conducted b y GlycoMimetics) was a 30 mg/mL solution for injection based on the salt of 
rivipansel which is equivalent to 28.28 mg/mL of the active moiet y rivipansel.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8103] of intravenous rivipansel 
on QTc interval in 48 healthy  African -American adult subjects ([COMPANY_007] Study  B5201001) has 
been completed. The rivipansel dose in the study  was 4 grams (expressed as active moiety ) 
asa single intravenous infusion and the active control was a single dose of moxifloxacin 
400mg orally .
The study  was deemed negative ; the statistical analy ses of the ECG measurements 
demonstrated a lack of a QTc effect with rivipansel compared to placebo as the upper bound 
of the 2- sided 90% confidence interval ( CI)for mean differences between rivipansel and 
placebo at all [ADDRESS_8104] -dose time points w asbelow the International Council for
Harmonisation ( ICH)E14 criteria of 10 milliseconds ( msec ).  The highest observed upper 
bound of the 2
-sided 90% CI s was 3.[ADDRESS_8105] -dose.  The moxifloxacin 
positive control performed as expected, thus the study  should be deemed adequatel y
sensitive .
Single doses of rivipansel were well tolerated in these health y male African -American 
subjects with an adverse event profile largel y consistent with that which had been reported in 
the previous studies undertaken b y GlycoMimetics . The only  new event reported was 
alanine aminotransfer ase(ALT) elevation that oc curred in a single male subject after 
receiving rivipansel. The AL T elevation was moderate (maximum ALT 3 times the upper 
limit of normal [ xULN]), was not associated with any  clinical signs or s ymptoms and 
recovered to normal levels on subsequent follow-up. The event was confounded by  [CONTACT_8857] a mildly  elevated ALT at baseline (<1.5xUL N) and having reported a 
previous epi[INVESTIGATOR_8809] “liver function test” elevation which occurred while 
participating in another healthy  volunteer drug study , undertaken at a different clinical 
research unit.
1.2.4. Study Rationale
Rivipansel is aglycomimetic inhibitor of E -
, P-, and L -selectins in vitro.  Rivipansel has been 
shown to inhibit inflammation in several animal models of disease, including the mouse 
model of vaso -occlusive crisis (VOC) of sickle cell disease (SCD).  It has also been shown to 
consistently  improve multiple clinically  meaningful measures of t he VOC experience, for 
both the pediatric and adult subjects enrolled in the Phase 2 study  (GMI -1070 -201).   This
Phase 3 study  will continue to examine rivipansel for the treatment of VOC in patients with 
SCD. 
1.2.5. Dose Rationale
Rivipansel
is administered int ravenously .  In this current Phase 3 study ,rivipansel IV 
solution for injection contains 30 mg/mL  of active moiety  rivipansel . 
The dosing regimen in this Phase 3 study  is as follows:
Subjects aged 12 and over who weigh >40kg, will receive study  drug as a loading 
dose of 1680 mg followed by  a maintenance dose of 840 mg every  122hours. 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 29Subjects aged [ADDRESS_8106] who weighs 40kg, will receive 
weight -based dosing (mg/kg) administered as a loading dose of 40 mg/kg (maximum 
of 1680 mg) followed b y a maintenance dose of 20mg/kg (maximum of 840 mg) 
every  122hours. 
The selection of the dose in this Phase 3 study  was based on efficacy , safety , and 
pharmacokinetic results from the Phase 2 study , where a low dose (20 mg/kg loading 
dose/10 mg/kg every  12hours ) and a high dose (40 mg/kg loading dose/20 mg/kg every  
12hours ) were studied (the doses were studied in a sequential fashion). In the Phase 2 study , 
the differences between the median time to discharge for rivipansel and placebo treatment 
groups were similar for the low rivipansel dose (56 hours) and the high dose (55 hours).  
Phase 2 treatment -emergent adverse events ( AEs)by [CONTACT_2715], as well as other safet y data, 
indicates there were no apparent safet y differences for either the low or high dose relative to 
placebo.   The pharmacokinetic data from the Phase [ADDRESS_8107] that the dose will result in exposures similar to that observed with the low 
dose in the Phase 2 study and a minimum plasma concentration above 10g/mL will be
maintained throughout the dosing interval.  This concentration has shown improved blood 
flow, rolling flux and survival rate in a SCD mouse efficacy  model.23In order for subjects 
12years of age not to exceed the high dose of 40/20 mg/kg studied in the P hase [ADDRESS_8108] not been previousl y 
studied.  I n the Phase 2 study , GMI - 1070- 201, subjects 12years old with the regimen of 
20mg/kg loading dose followed by  10mg/kg every  [ADDRESS_8109] similar exposures. The simulations showed that for 
children 6 to 11 years old, a 40mg/kg loading dose (maximum 1680 mg) followed by  
20mg/kg every  12 hours (maximum 840 mg) will result in concentrations similar to those 
observed with the 20/10 mg/kg dosing in 
the GMI -1070-201 study .
1.3.
Summary of Benefit Risk Assessment
The available safet y results from non- clinical and clinical studies support further 
investigation of rivipansel in subjects. 
The beneficial effects of rivipansel are postulated to be the result of mechanism -based 
resolution of VOC via the inhibition of selectin -mediated adhesion of leukocy tes to the 
endothelium.  This prevents propagation of the vaso- occlusion and promotes earl y resolution 
of the VOC epi[INVESTIGATOR_1865]. 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 333.STUDY DESIGN
3.1.Study Overview
This Phase 3 randomized , double -blind, placebo- controlled, parallel group, multicenter study  
is designed to demonstrate the efficacy  of rivipansel in treating subjects with SCD who are 
6years of age experiencing an acute VOC event necessitating hospi[INVESTIGATOR_059].  This study  
has two cohorts: Cohort 1 includes one adult stratum ( ≥18 y ears old) and one pediatric 
stratum (12- 17 years old), Cohort 2 includes one pediatric stratum (6 -11 years old). The 
primary  anal ysis popu lation will be Cohort 1 and Cohort 2 combined (see Section 9.1) but 
thetwo cohorts will also be anal ysed separatel y.
There are two entry  points into this study .  The first point of entry  is referred to as 
“Pre-VOC/Study  Entry  Screening” and occurs while the subject is well.  The second entry  
point is while the subject is experiencing a pain crisis and is termed “ VOC/ Treatment -Ready  
Screening”.
Pre-VOC/Study  Entry  Screening : Investigators may  choose to identify , through chart review, 
those subjects who may be appropriate for the study  before they  develop VOC.  These 
subjects may  be educated about the study when they  are well, such as in the office setting ,
and approached for consent/assent while not experiencing a pain crisis.  The sesubject swill 
receive monthly  telephone calls from the study  site staff (or attend clinic visits, if preferred) 
until the time of their next VOC necessitating hospi[INVESTIGATOR_059] . At the time of VOC, the 
subject will be asked if they  want to continue participating i
nthe VOC/ Treatment- Read y 
Screening and if eligible, be randoml y assigned to blinded study  drug . The subject’s 
affirmation must be documented .
VOC/Treatment -Ready  Screening : In addition to approaching subjects prior to VOC, 
investigators are encouraged t o identify  subjects with VOC in settings that could include 
emergency  department , clinic, day  hospi[INVESTIGATOR_8810], who are 
planned or likel y to be admitted to the hospi[INVESTIGATOR_307] , and approach them for consent/assent and 
eligibility  criteria earl y in the process of treatment for VOC. 
Subjects with acute VOC who complete the VOC/Treatment- Ready  screening assessments 
and meet all eligibility  criteria are enrolled into the study  and will be randomized in a 
1:1ratio to receive multiple IV doses of rivipansel or placebo for the treatment of VOC.
  
Randomization will be stratified b y age(6-11, 12- 17, and 18years of age) and genot ype 
(category  1: HbSS ,HbS0thalassemia and HbSD; category  2:HbSC ,HbS+thalassemia and 
HbS-Variant [other than HbSD]). 
Dosing of eligible subjects with acute VOC will be initiated as earl y as possible, but no l ater 
than [ADDRESS_8110] dose of IV opi[INVESTIGATOR_2438].  For subjects ag ed 
12and over who weigh >40 kg, study  drug will be administered as a loading dose of 
1680 mg followed b y a maintenance dose of 840 mg every  12[ADDRESS_8111] who weigh s40kg, will receive a loading dose of 40mg/kg 
(max imum of 1680 mg) followed by  a maintenance dose of 20mg/kg (max imum of 840mg)
every  122hours.  S tudy drug will be administered until criterion 1 of the
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8112]’s hospi[INVESTIGATOR_8811]’s participation 
in the study  may  exceed 4 4days.
Subjects who enter the Pre-
VOC period of the study  while well (ie, not in VOC ) will 
participate in the stud y for more than [ADDRESS_8113] on the study (ie, Last Subject Last Visit)
.
4.SUBJECT SELECTION
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility criteria are designed to select subjects for whom protocol treatment is considered 
appropriate.  All relevant medical and non -medical conditions should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol.
An eligibility  card will be provided to ensure review of all inclusion and exclusion criteria.
4.1. Inclusion Criteria
Subject eligibility should be reviewed and documented by  [CONTACT_4653]’s stud y team before subjects are included in the study .
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
1.6years of age .
2.Documented diagnosis of sickle cell disease (HbSS, HbS -thalassemia [HbS0and 
HbS+thalassemia] ,HbSC orHbS-Variant, including HbSD and HbSE).
3.
Diagnosis of VOC at the time of enrollment; necessitating admission to the hospi[INVESTIGATOR_8812] .  This applies to the VOC/Treatment -Read y Screening 
entry  point.
4.Able to commence the first dose of study  drug within [ADDRESS_8114] dose of IV opi[INVESTIGATOR_2438] ( Subjects treated as an outpatient within the past [ADDRESS_8115] dose of IV opi[INVESTIGATOR_8813]).
5.Evidence of a personally  signed and dated informed consent (and assent, where 
applicable) document indicating that the subject (or a legall y acceptable 
representative/parent(s)/legal guardian ) has been informed of all pertinent aspects of the 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 38study .  This applies to consent/assent at the time of Pre- VOC/Study  Entry  Screening or
VOC/Treatment -Ready  Screening.
6.Subjects who are willing and able to compl
y with scheduled visits, treatment plan, 
laborat ory tests, and other study  procedures .
7.Male subjects able to father children and female subjects of childbearing potential and at 
risk for pregnancy  must agree to use a highl y effective method of contraception 
throughout the duration of the active treatmen t period (starting at 
VOC/Treatment -Read y 
Screening )and for at least [ADDRESS_8116] dose of assigned treatment.  
Female subjects who are not of childbearing potential (ie, meet at least one of the 
following criteria):
Have undergone a documented hysterectomy  and/or bilateral oophorectomy ;
Have medically  confirmed ovarian failure ;  
Have a chieved post -menopausal status, defined as cessation of regular menses for 
at least 12 consecutive months with no alternative pathological or phy siological 
cause and a serum follicle -stimulating hormone ( FSH)level confirming the 
post-menopausal state .  If FSH result is not available by  [CONTACT_8858]’s 
judgment and subject’s 
medical history .
All othe r female subjects (including females with tubal ligations and females that do 
NOT have a documented hy sterectom y, bilateral oophorectom y and/or ovarian 
failure) will be considered to be of childbearing potential.
4.2. Exclusion Criteria
Subjects presenting with any of the following ,from the time of VOC/Treatment- Read y 
Screening up to the time of randomization unless otherwise stated, will not be included in the 
study :
1.Serious sy stemic infection , evidenced b yclinical signs and s ymptoms, and/or 
microbiological i
nvestigations, consistent with this diagnosis.  Subjects with fever < 39 °C 
(
102.2°F ) may  be considered for enrollment if in the opi[INVESTIGATOR_8814] y serious sy stemic infection. Subjects with fever ≥ 39 C (102.2F) are 
excluded.
2.Subjects presenting with the following clinical risk factors of acute chest sy ndrome : 
Hypoxia –defined as O 2saturation of <90% ( by [CONTACT_406] ) on room air on 
2separate readings 15 minutes apart, or single value of PaO 2<60 mm
Hgon 
arteria l blood gas,
and/or
Hemoglobin <5 gm/dL.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8117] sy ndrome , at the time of presentation , as defined b y the National I nstitutes of 
Health ( NIH)treatment guidelines :24,[ADDRESS_8118] one complete lung segment consisten t with 
the presence of alveolar consolidation, ( excluding atelectasis) AND one or more of the 
following :
Chest pain;
Temperature >38.5oC
;
Tach ypnea ;
Wheezing or rales ;
Cough .
4.SCD pain aty pi[INVESTIGATOR_8815], including hepatic or splenic sequestrati on, cholecy stitis, or 
pneumonia.
5. At the time of presentation:
acute stroke ,or
severe avascular necrosis of the hip/shoulder when the presenting pain is only  in 
the affected hip/shoulder .
6. E stimated glomerular filtration rate (eGFR)  60 mL/min/1.73 m2(refer to 
Appendix 1for calculation) .
7. H istory  consistent with rapi[INVESTIGATOR_8816], in 
the opi[INVESTIGATOR_871] .
8.Alanine aminotransfer ase (ALT/SGPT) >3 times the upper limit of normal (X ULN)
(based on clinic laboratory normal range) .
9.Platelets <50,000/mm3.
10.Subjects currentl y receiving transdermal analgesics and/or the expectation that 
transdermal analgesics may  beused during the study for treatment of this epi[INVESTIGATOR_8817] (see Section 5.8.2) .
11.Recent (within the past 30 days) major surgery (see definition in Section 4.3.2), 
hospi[INVESTIGATOR_8818], documented serious infection requiring IV 
antibiotic treatment, or significant bleeding.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 4012.Hospi[INVESTIGATOR_8819], or treat ment with parenteral pain medications in 
other medical settings such as the emergency  department or day  hospit al for 
uncomplicated VOC, from 48hours to 14daysprior to admitting presentation. 
Subjects may  be included if treated as an outpatient within the p ast 48 hours for 
the same VOC epi[INVESTIGATOR_1865].
13.Recent (within the past 14days) diagnosis of cerebrovascular accident, or transient 
ischemic attack .
14.Greater than [ADDRESS_8119] 6 months (180 days).
15. Other severe acute or chronic m edical or ps ychiatric condition or laboratory abnormality  
that may  increase the risk associated with study  participation or study  drug administration 
or may  interfere with the interpretation of study  results and, in the judgment of the 
investigator, would make the subject inappropriate for entry  into this study .
16.Any condition(s) that compromises the subject’s ability  to comply  with and/or perform 
study -related activities or that poses a clinical contraindication to study  participation 
(these conditions incl ude, but are not limited to, inadequate medical history to assure 
study  eligibility ; inadequate venous access).
17.Subjects previous ly randomized in the current study .
18. Participation in other studies involving investigational drug(s) (Phases 1- 4) within 
4weeks before the current study  begins and/or during stud y participation .
19.Expectation that the subject will not be able to be followed for the duration of the study .
20.Pregnant female subjects orbreastfeeding female subjects ;
21. M ale subjects able to father ch ildren and female subjects of childbearing potential who 
are unwilling or unable to use a highly  effective method of contraception as outlined in 
this protocol for the duration of the active treatment period (starting at 
VOC/ Treatment -Ready  Screening) and for at least [ADDRESS_8120] of the 
study .
23.
Active use of illicit drugs and/or alcohol dependence, as determined b y the investigator .
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8121] agree to use a highly effective method of contraception consistentl y and correctly for 
the duration of the active treatment period ( ie, starting at the time of VOC/ Treatment -Ready  
Screening) andforat least [ADDRESS_8122] dose of study  drug .  The investigator or 
his/her designee , in consultation with the subject, willconfirm the subject has selected an 
appropriate me thod of contraception for the individual subject and their partner from the 
permitted list of contraception methods (see below) , and instruct the subject in its consistent 
and correct use.  Subjects need to affirm that they  meet the criteria for correct use of at least 
one of the selected methods of contraception.  The investigator or his/her designee will 
discuss with the subject the need to use highl y effective contraception consistently  and 
correctly  according to the Schedule of Activities ( see Table 1) and document such 
conversation in the subject’s chart.   In addition, the investigator or his/her designee will 
instruct the subject to call immediately  if the selected contraception method is discontinued 
or if pregnancy  is known or suspected in the subject or the subject’s partner. 
Highl y effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and c orrectly  (ie,perfect use) and 
include:
1.Established use of oral, inserted, injected ,implanted or transdermal hormonal 
methods of contraception are allowed provided the subject plans to remain on the 
same treatment throughout the entire study  and has been using that hormonal 
contraceptive for an adequate period of time to ensure effectiveness .
2.Correctl y placed copper -containing intrauterine device (IUD).
3.Male condom or female condom used WITH a spermicide (ie ,foam, gel, film, cream, 
suppository ).  For cou ntries where spermicide is not available or condom plus 
spermicide is not accepted as highl y effective contraception, this option is not 
appropriate.
4.Male sterilization with absence of sperm in the post -vasectom y ejaculate .
5.Bilateral tubal ligation / bilat eral salpi[INVESTIGATOR_8820] y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label).
4.3.2. Surgery
Elective Surgery : Elective surgery  during the active treatment period ( ie, starting at the time 
of VOC/ Treatment -Ready  Screening) through Day  35Post-Discharge Follow -Upvisit, 
should not be scheduled without first consulting with the 
[COMPANY_007] medical monitor. 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 42Non-elective Surgery : Investigators should contact [CONTACT_8859]- elective surgery  to discuss their suitability  to remain in the study .
As indicated, recent major surgery  is an exclusion criterion for this study .  For the purposes 
of this study , major surgical intervention is defined as surgery  involving op en abdominal, 
intracranial or complex orthopedic procedures . Retroperitoneal and thoracic procedures are
alsoconsidered major surgery .  For other major surgeries contact [CONTACT_456]’s medical 
monitor .
4.4.Sponsor Qualified Medical Personnel
The contact [CONTACT_8860]'s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_8861].
To facilitate access to appropriatel y qualified medical personnel on stud y related medical 
questions or problems, subjects are provided with a contact [CONTACT_1137]. The contact [CONTACT_4662], 
at a minimum, protocol and investigational compound identifiers, subjec t study  number, 
contact [CONTACT_8862] (study ) site and contact [CONTACT_4664] a contact [CONTACT_8863] a medical 
question or problem originating from another healthcar e professional not involved in the 
subject ’s participation in the study . The 
contact [CONTACT_8864], however it should only  be used in 
the event that the established communication pathway s between the study  site and the 
sponsor 
study  team are not available. It is therefore intended to augment, but not replace the 
established communication pathway s between the study  site and the sponsor study  team for 
advice on medical questions or problems that may arise during the study (consult the Study  
Reference Manual for additional details on communication pathway s and contact 
[CONTACT_3031]) . The contact [CONTACT_8865] b y the subject directly and if a 
subject calls that number they  will be directed back to the study  site.
5.STUDY TREATMENTS
For the purposes of this study , and per International C ouncil on Harmonisation (ICH) 
guidelines, investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference/comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (I CH E6 1.33).  
For this study , the investigational products are Rivipansel and a phosphate buffered saline 
Placebo.
Subjects will be randomized at a 1:1 ratio to one of two treatment groups:
Rivipansel
;
Placebo.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 45clear ,but a fine swir l or haze of particulate matter may  be observed on agitation of the 
solution .
A phosphate buffered saline (PBS) placebo, clear, color less solution will also be supplied by  
[CONTACT_456].  The placebo will be supplied as a sterile solution for single use administration 
in a30mL clear glass vial sealed with a grey stopper and aluminum over -seal for 
administration by  [CONTACT_5204].
Vials will be packaged in individual cartons and identified with a unique identification ( ID)
number for subsequent un it dose preparation according to the Investigational Product (IP) 
Handling Manual . 
Each packaged lot of blinded drug supplies will look visually  identical up to the carton 
containing the vials being opened. Therefore when the drug supplies are received at the site 
no special procedures are required to maintain the blind ( ie,both the active and placebo vial 
cartons should be handled and stored the same )
.  However, t o avoid unblinding due to 
potential color difference between the active and placebo soluti ons, 
only unblinded study  site 
staff should open the 
cartons containing the vials. 
Vial adapters and s yringe filters will be supplied by  [CONTACT_8866].  
For further details regarding the composition of the drug product and the placebo , please 
refer to the Investigator Brochure for [COMPANY_007] compound PF-06460031 (GMI -1070, rivipansel ).
5.4.2. Preparation and Dispensing
The randomization sy stem will identify  the specific vials to be used to prepare the dose for 
each subject according to the random
ization list.
Subjects aged 12 and over who weigh >40kg, will receive a loading dose of 1680 mg 
followed b y a maintenance dose of 840 mg every  122hours.  Two vials will be assigned 
by [CONTACT_8867] a single vial for each of the subsequent 
maintenance doses.
Subjects aged [ADDRESS_8123] who weigh s40 kg, will receive aloading dose of 
40mg/kg (maximum of 1680 mg) followed b y a maintenance dose of 20 mg/kg (ma ximum 
of 840 mg) every  122hours.  The weight measured as part of the VOC/Treatment -Ready  
screening procedures will be used to determine the appropriate dose to be administered 
during the stud y. 
Study drug will be administered until criterion 1 of the readiness -for-discharge criteria (see
Section 7.1.1) has been met , or up to 15 doses of study  drug (1 loading dose and a maximum 
of 14 maintenance doses), whichever comes first. 
Active or placebo sterile solution for intravenous infusion will be prepared and stored 
according to details specified in the IP Handling Manual .  
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

P F -[ADDRESS_8124] ( or desi g nee) will pre pare t he st u d y  dr u g a n d, as descri be d i n t he 
I P Ha n dli n g Ma n ual , t his will i ncl u de t he re q uire me nt f or t he st u d y  dr u g t o be filtere d u p o n 
tra nsfer t o t he i nf usi o n ba g or s yri n ge t hr o u g h a 0. [ADDRESS_8125] ( or desi g nee) will pre pare t he st u d y dr u g i n a ma n ner t hat will 
c o nceal a n y p ote ntial c ol or differe nce bet wee n t he acti ve a n d place b o s ol uti o ns , as descri be d 
i n t he I P Ha n dli n g Ma n ual .  F or i nf usi o ns a d mi nistere d wit h a s yri n ge p u m p , t he s p o ns or will 
pr o vi de sites wit h ti nte d tra nsl uce nt ta pe t o c o ver t he s y ri n ge a n d t he i n -li ne filter i n t he I V 
li ne .  F or i nf usi o ns a d mi nistere d via i nf usi o n ba g, s p o ns or -pr o vi de d c o vers will be place d 
o ver t he ba g a n d ti nte d tra nsl uce nt ta pe will be use d t o c o ver t he dri p c ha m ber a n d t he i n -li ne 
filter i n t he I V li ne.   T he u n bli n de d p har macist ( or desi g nee) will la bel t he st u d y  dr u g i n a 
ma n ner t hat d oes n ot i de ntif y t he c o nte nts.  Bli n de d site staff will recei ve t he st u d y  dr u g i n a 
bli n de d ma n ner fr o m t he p har mac y .
5. 5. A d mi nistr ati o n 
D osi n g of eli gi ble s u bjects will be i nitiate d as earl y as p ossi ble, b ut n o l ate r t ha n [ADDRESS_8126] u d y  treat me nt will be a d mi nistere d 
e ver y  1 2 2h o urs u ntil criteri o n 1 of t he rea di ness -f or -disc har ge criteria (see Secti o n 7. 1. 1 )
has bee n met , or u p t o [ADDRESS_8127] u g ( 1 l oa di n g d ose a n d a ma xi m u m of 
1 4 mai nte na nce d oses), w hic he ver c o mes first. 
Pri or t o i nitiati o n of st u d y  dr u g i nf usi o n, t he I V access s h o ul d be fl us he d wit h n or mal sali ne 
t o pre ve nt a n y p ote ntial i nc o m pati bilities wit h resi d ual s ol uti o ns i n t he access li ne.  
Ri vi pa nsel or place b o s ol uti o n will be i nf use d i ntra ve n o usl y o ver a peri o d of 2 0 mi n utes ( u p 
t o 4 0 mi n utes is all o wa ble) fr o m t he start of t he st u d y  dr u g I V i nf usi o n usi n g a n 
a d mi nistrati o n set t hat i ncl u des a 0. [ADDRESS_8128] u g 
A d mi nistrati o n G ui da nce D oc u me nt .
T h e  p l a n n e d  s c h e d u l e  f o r  d o s i n g  e v e r y  1 2 2h o u r s  s h o u l d  r e m a i n  a s  
pl a n ne d, i r r e s p e c t i v e  o f  a d j u s t m e n t s  f o r  t i m i n g  b a s e d  o n  t h e  2 h o u r  w i n d o w  
f o r  d o s i n g .   D o s i n g  s c h e d u l e  s h o u l d  n o t  b e  a d j u s t e d  f o r  a c t u a l  d o s i n g  
t i m e s .   S e e  e x a m p l e  i n  Ta ble 2b e l o w . 0 9 0 1 7 7 e 1 9 1 5 d a 0 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 6- J ul- 2 0 1 9 1 8: 4 4 ( G M T) 
PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 47Table 2. Sample Dosing Schedule (example of acceptable dosing schedule)
Dose Planned Start 
Time Actual Start Tim e
First dose /Loading dose (am) 9am 9am
Second dose (pm) 9pm [ADDRESS_8129] dose (am) 9am 8:30 am
Fourth dose (pm) 9pm 10:30 pm
Rivipansel sterile solution has been shown to be compatible with 5% Dextrose in Water 
(D5W), Normal S aline (0.9% sodium chloride, [NS]), or any combinations of the two; for 
example, 5% Dextrose in 0.9% sodium chloride (D5/NS ), 5% Dextrose in 0.45% sodium 
chloride ( D5/½ NS ), and 5% D extrose in 0.225% sodium chloride (D5/ ¼ NS). Any of these 
solutions may be co-administered alone or in combination with up to 20 mEq/L KCl. 
Co-administration with any  other IV medications or fluids administered through the same 
IVline is not permitted. 
5.6.Drug Storage 
Vials of rivipansel and placebo solutions are required to be stored in their original container 
and in accordance with the study  drug label.
The investigator, or an approved representative, eg, pharmacist, will ensure that all study  
drug, including placebo, are stored in a s ecured area with controlled access under 
recommended storage conditions and in accordance with applicable regulatory  requirements.
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated and/or room temperature products).  This should be 
captured from the time of study  drug receipt throughout the study .  Even for continuous 
monitoring sy stems, a log or site procedure which ensures active evaluation for excursions 
should be available.  The intent is to ensure that the minimum and maximum temperature is 
checked each business day to confirm that no temperature excursion occurred since the last 
evaluation and to provide the site with the capability
 to store or view the minimum/maximum 
temperature for all non- working day s upon return to normal operations.  Theoperation of the 
temperature monitoring device and storage unit (for example, refrigerator), as app licable, 
should be regularl y inspected to ensure they aremaintained in working order.
Any excursions from the product label storage conditions should be reported to [COMPANY_007] upon 
discovery . The site should activel y pursue options for returning the product t o labeled storage 
conditions, as soon as possible.  Deviations from the storage requirements, including an y 
actions taken, must be documented and reported to [COMPANY_007] .  
Once an excursion is identified, the study  drug must be quarantined and not used until [COMPANY_007]
provides 
documentation of permission to use the study  drug .  It will not be considered a 
protocol deviation if [COMPANY_007] approves the use of the investigational product after the 
temperature excursion.  Use of the investigational product prior to [COMPANY_007] approval will be 
considered a protocol deviation.  Specific detail s regarding information the site should report 
for each excursion will be provided to the site.   
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8130](s) are briefl y out of labeled temperature range are no t considered excursions.
More specific details will be provided to the sites separately .  Refer to theInvestigational 
Product manual for additional details regarding excursion reporting requirements for the 
sites.  
5.7.
Drug Accountability
The investigator’s site must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the drug supplies.  Study  drug inventory  and accountability  forms will be 
maintained by  [CONTACT_8868], and examined and reconciled by  [CONTACT_8869].
The sponsor, or designee, will provide guidance on the destruction of unused study  drug (eg, 
at the site).   If destruction is authorized to take place at the study  site, the investigator must 
ensure that the materials are destro yed in compliance with applicable environmental 
regulations, institutional policy , and any  special instructions provided by  [CONTACT_8870].
5.8.Concomitant Treatment (s)
5.8.1. Prohibited Prior to Study Entry
Subjects receiving transdermal analgesics at the time of study  entry  will be excluded from 
enrolling into the stud y. 
Active use of illicit drugs at the time of study  entry  is prohibited.  T he term “illicit drugs” 
includes, but is not limited to, cocaine, heroin, ecstasy , and phency clidine (commonly  known 
as ‘PCP’).  I nvestigators are encouraged not to enroll subjects for whom inappropriate use of 
prescribed opi[INVESTIGATOR_8821].
5.8.2. Prohibited During the Study
Use of transdermal analgesics ( including, but not limited to fentany l orlidocaine patches )is 
not allowed for treatment of the qualify ing epi[INVESTIGATOR_8822]. The following 
are not consi dered transdermal analgesics : Transcutaneous Electrical Nerve Stimulation 
(TENS) units; skin patches that only  deliver heat therapy  such as a ThermaCare® patch ,
topi[INVESTIGATOR_8823], gels ,or ointments (such as L idocaine cream) , or topi[INVESTIGATOR_8824] s, provided they  are not being administered to treat the epi[INVESTIGATOR_8825] .
Systemic steroid therap y used specifically  for the treatment of a n uncomplic atedVOC is not 
permitted during the study.   However, sy stemic steroid usefor other indications (eg, severe 
reactive airway  disease ) is allowed.
5.8.3. Permitted During the Study
Treatments intended for other indications may be administered as usual.   The use of inhaled 
or topi[INVESTIGATOR_8826], h ydrox yurea, and nonsteroidal anti -inflammatory  drugs (NSAIDs)will be 
allowed.  The use of medical marijuana is not excluded for the purposes of this study .  
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 49All concomitant treatments taken during the study  (1week prior to signing or affirming 
VOC/Treatment -Ready  informed assent/consent and through the last post -dose follow -up 
assessment) should be recorded in the source document and Case Report Form ( CRF ).All 
concomitant treatments should be confirmed and reviewed b y the investigator or his/her 
designee prior to each dose for the durat ion of the study .  
5.8.4. Pain Management
Pain management should follow the usual standard of care considering the institution’s usual 
procedures and determined by  [CONTACT_8871], emergency medicine staff , pain specialist, hospi[INVESTIGATOR_8827].  
Specific medications, dosing and infusion parameters should be individualized according to 
the subject ’s acute pain characteristics taking into account past medical history , concomitant 
medications, concurrent clinical concerns, and protocol restrictions as noted in Section 5.8.2..  
The following suggestions are offered to standardize management :
Recommended IV pain medications include , but are not limited to, morphine, 
hydromorphone, ketorolac, or fentany l, used in a ccordance with standard clinical 
practice .  Study  site staff should contact [CONTACT_4618]’s medical monitor when considering 
medica tions not included in this list;
Initial treatment should aim to achieve pain control; pain control is defined as pain 
that does not require further escalation of pain medication OR subject reports pain is 
controlled ;
Ongoing treatment should aim to maintain pain control; consider weaning IV opi[INVESTIGATOR_8828];
Patient
-controlled analgesia (PCA) use (basal and bolus dosing ) is encouraged for all 
subjects, per hospi[INVESTIGATOR_8829] ;
In addition to IV pain medications , subjects should receive other supportive care and 
treatments according to standard of care .  These may  include, but are not limited to, 
the following:
adequate h ydration per routine procedure ;
incentive spi[INVESTIGATOR_8830]/or other respi[INVESTIGATOR_8831]
(which arehighly  encouraged);
supplemental ox ygen
adjunctive mechanical treatments such as massage, application of heat packs, 
etc.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 526.1.Screening
6.1.1. Pre-VOC/Study Entry Screening
[IP_ADDRESS]. Consent of Subjects
A written, [COMPANY_007] and institutional review board (IRB)/ ethics committee (EC) -approved, 
informed consent/assent (as appropriate) must be obtained before initiating study  procedures.  
See Section 12.3.
Investigators 
may choose to identify , through chart review, those subjects who may  be 
appropriate for the stud y before they  develop VOC.  These subjects may be educated about 
the study when they  are well, such as in the office setting ,and approached 
for consent/assent while not experiencing a pain crisis. 
After consent, subject information will be entered into the sponsor’s randomization sy stem to 
document the subject has en tered into the Pre -VOC/Study  Entry  Screening period.  A subject
identification number will be generated . Serious adverse events must be reported to [COMPANY_007] 
from the time of signing Pre- VOC/Study  Entry  informed consent.
Formal assessment for eligibility  will not be performed at this time.  No blood samples will 
be collected for laboratory  analy sis.  The subject will not be enrolled, or randomized to a 
treatment arm at this time.  Subjects who sign consent pre -VOC may discontinue the study  at 
any time . At the time of VOC, the subject will be asked if they  want to continue 
participating in the VOC/ Treatment -Ready  Screening and if eligible, be randomly  assigned to 
blinded study  drug .
The subject’s affirmation must be docume nted.
These subjects will have the option of us inga transportation service to take them to and from
the hospi[INVESTIGATOR_8832] .
[IP_ADDRESS]. Monthly Telephone Contacts
Study sitestaff will be encouraged to contact [CONTACT_8872]  4weeks
(7days).  During these phone contacts, the study site staff will ask the subject how they  
have been feeling, as well as remind the subject about the appropriate procedures to follow 
when experiencing a n acute VOC event necessitating hospi[INVESTIGATOR_059] (including use of the 
transportation service provided by  [CONTACT_456]) .  If the subject or investigator prefer, the 
monthly  contacts may  be a clinic visit.   
6.1.2.
VOC/Treatment- Ready Screening
[IP_ADDRESS]. Visit 1, VOC/Treatment- Ready Screening
In addition to consenting a subject in the office setting, prior to a pain crisis, some subjects 
may be initially  approached for consent when presenting to the emergency  room/clinic in 
VOC.  Investigators are encouraged to identify  subjects with VOC who are planned or likely 
to be ad
mitted, and approach them for consent/assent and eligibility  criteria earl y in the 
process of treatment for VOC. 
A written, [COMPANY_007] and institutional review board (IRB)/ethics committee (EC) -approved, 
informed consent/assent (as appropriate) must be obtain ed before initiating study  procedures.  
See Section 12.3.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8131] Si ckle Cell Disease -specific history  (eg, SCD genot ype, start time of this 
VOC event, medications used to treat this pain event, frequency  of painful cris es 
requiring hospi[INVESTIGATOR_059], SCD related complications such as history  of ACS, 
priapi[INVESTIGATOR_8801] ,etc).
12.Record prior and concomitant medication : all medications administered within 
1week o f signing the VOC/T reatment - Ready informed assent/ consent or affirmation 
of informed consent (if applicable) .  
13.Record prior and on -going parenteral opio ids administered.
14.
Record prior and concomitant non-drug treatments/procedures: all non- drug 
treatments/procedures administered within 1 week of signing the 
VOC/Treatment -Ready  informed assent/consent or affirmation of informed consent
(if applicable) .
15.
Review and confirm stu dy eligibility  criteria.
16.If subject has met all eligibility  criteria, enter subject information using sponsor’s 
electronic randomization system to document the subject has been enrolled and obtain 
randomization information .
If the subject is determined to be a screen failure due to inability  to initiate dosingwithin
24hours from the administration of the first dose of IV opi[INVESTIGATOR_2438], presence of serious infection, 
ACS, or other recent clinical events excluding the subject from participating , rescreening will
be allowed at the time of the subject’s next VOC , pending approval from the sponsor’s 
medical monitor .  All screening procedures would have to be repeated, including the consent 
process , as part of the re -screening process
. 
6.2.Study Period
6.2.1. Visit 1, Day 1 –Loading Dose
All subjects should be dosed with study  drug as early  as possible, but the start of study  drug 
dosing should be no later than [ADDRESS_8132] dose of IV 
opi[INVESTIGATOR_2438]
.
At this visit, the following will be performed:
1.Record adverse events.
2. Record concomitant medications, including parenteral opi[INVESTIGATOR_2441].  Record IV opi[INVESTIGATOR_8833]  4hours for the first 48hours from the start time of the study  
drug loading dose .
3.
Record concomitant non- drug treatments/proc edures.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

P F -[ADDRESS_8133]- Disc h ar ge F oll o w -U p P h o ne C all 
A p pr o xi matel y  7 ( 3) da y s after disc har ge, t he i n vesti gat or ( or desi g nee) will c o ntact t he 
s u bject b y  tele p h o ne i n or der t o c ollect i nf or mati o n re gar di n g t he occ urre nce of a n y A Es , t he 
use of c o nc o mita nt me dicati o ns a n d treat me nts/ pr oce d ures , a n d t o re mi n d t he s u bject a b o ut 
usi n g a p pr o priate c o ntrace pti o n (if a p plica ble) a n d t he u pc o mi n g Da y [ADDRESS_8134] -Disc har ge 
F oll o w -U p visit ( N ote: If t he s u bject or i n vesti gat or prefer, t he Da y  [ADDRESS_8135] 
ma y  be a cli nic visit ).   
 
6. 4. 2. Visit 3, D a y [ADDRESS_8136] -Disc h ar ge F oll o w -U p P h o ne C all 
A p pr o xi matel y  2 1 ( 5) da y s after disc har ge, t he i n vesti gat or ( or desi g nee) will c o ntact t he 
s u bject b y  tele p h o ne i n or der t o c ollect i nf or mati o n re gar di n g t he occ urre nce of a n y A Es, t he 
use of c o nc o mita nt me dicati o ns a n d treat me nts/ pr oce d ures , a n d t o re mi n d t he s u bject a b o ut 
usi n g a p pr o priate c o ntrace pti o n (if a p plica ble) a n d t he u pc o mi n g Da y  [ADDRESS_8137] -Disc har ge 
F oll o w -U p visit ( N ote: If t he s u bject or i n vesti gat or prefer, t he Da y  [ADDRESS_8138] ma y  be a cli nic visit ). 
6. 4. 3. Visit 4, D a y [ADDRESS_8139] -Disc h ar ge F oll o w -U p / E arl y Ter mi n ati o n 
T he f oll o wi n g acti vities are t o be perf or me d 3 5 (5) da y s after disc har ge.  H o we ver, if t he 
s u bject is e x perie nci n g a V O C or ot her ac ute S C D- relate d e ve nt ,t he visit s h o ul d be dela y e d 
u ntil t he ac ute e ve nt has res ol ve d .  If t he s u bject ter mi nates fr o m t he st u d y  earl y, t hese sa me 
pr oce d ures are t o be perf or me d n o s o o ner t ha n [ADDRESS_8140] a tar gete d p h ys ical e xa m assessi n g t he f oll o wi n g at a mi ni m u m: s ki n, c hest, 
res pi[INVESTIGATOR_1305] y , car d i o vasc ular, a b d o m i nal a n d m usc ul os keletal s y ste ms .  Partic ular atte nti o n 
will be directe d at areas affecte d b y pai n.  A d d i t i o n a l  b o d y  s y s t e m s  m a y  b e  
e x a m i n e d  a t  t h e  d i s c r e t i o n  o f  t h e  i n v e s t i g a t o r . 
2. Rec or d a d verse e ve nts. 
3. Rec or d c o nc o mita nt me dicati o ns. 
4. Rec or d c o nc o mita nt n o n -dr u g treat me nts/ pr oce d ures. 
5. C ollect vital si g ns (te m perat ure [ Celsi us], res pi[INVESTIGATOR_1305] y rate, p ulse, bl o o d press ure, a n d 
p ulse o xi me tr y ). 
6. C ollect bl o o d sa m ples f or: 
He mat ol o g y  pa nel (see Ta ble 3); l ocal la b orat or y ;
Ser u m C he mistr y  (see Ta ble 3); l ocal la b orat or y ;0 9 0 1 7 7 e 1 9 1 5 d a 0 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 6- J ul- 2 0 1 9 1 8: 4 4 ( G M T) 
PF-[ADDRESS_8141] should 
complete the procedures as per the End of Treatment visit (Visit 1, see Table 1, Schedule of 
Activities
) at the time of the study  discontinuation or as soon as possible thereafter .  Subjects 
withdrawn from the study after End of Treatment or Discharge should return for safety  
evaluation as per Day 35Post-Discharge Follow -Up visit (Visit 4) no sooner than [ADDRESS_8142]’s condition.
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety  or behavioral 
reasons, or the inability  of the subject to compl y with the protocol required schedule of stud y 
visits or procedures at a given stud y site.  In an y circumstance, every  effort sh ould be made 
to document subject outcome , if possible.  The investigator should inquire about the reason 
for withdrawal, request the subject to return for a final visit, if applicable, and follow -up with 
the subject regarding an y unresolved adverse events.
If a subject does not return for a scheduled visit, every  effort should be made to contact [CONTACT_1560].  All attempts to contact [CONTACT_8873]’s medical record.  In accordanc e with due diligence 
requirements, if a subject fails to return for scheduled visit(s), the site shall record 
information concerning attempts to contact [CONTACT_8874], 
including method of contact (eg, letter, phone call) and d ate of each attempted contact.  It is 
recommended that the investigational site makes two phone calls to asubject who missed the 
visit, documenting each call in the source documents.  A third contact [CONTACT_8875] a 
certified letter to the subject, an d this letter and the response received become part of the 
source documents.  Ifa site has made at least [ADDRESS_8143] to follow up (L TFU).  
Subject’s status sh ould be designated LTFU in the CRF and in the study  monitoring report.
If it is determined that the subject has died, the site will use permissible local methods to 
obtain the date and cause of death.  If after all attempts, the subject remains L TFU, then the 
last known alive date as determined by [CONTACT_8876]’s medical records.   If the subject returns to the site bey ond [ADDRESS_8144] -
discharge after having been determined to be LTFU, V isit 4, Day  35 study  procedures do not 
need to be performed.  Any  safet y events (SAE/AEs) that occurred up to the date when the 
subject’s Visit 4, Day  [ADDRESS_8145] occurred are to be recorded in both the 
medical records and the eCRF.  In addition, SAEs (including an y SAEs that may have 
occurred bey ond the subject’s Visit 4, Day  35Post Discharge )will be reported as defined in 
Section 8.[ADDRESS_8146] withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8147] cannot be performed the 
investigator will document the reason for this and any corrective and preventive actions 
which he/she has taken to ensure that normal processes are adhered to as soon as possible.  
The sponsor study  team will be informed of these incidents in a timely  fashion.
7.1.Efficacy
Methods of measuring the efficacy  of rivipansel in treating subjects hospi[INVESTIGATOR_8834] y are described in this section .
7.1.1. Readiness- for-Discharge Criteria
The primary  endpoint istime toreadiness -for-discharge, where readiness -for-discharge is 
met when all o
f the applicable 6criteria are documented to have occurred –the criteria are to 
be assessed in relation totreatment for this VOC event andacute complication (s)directl y 
related to this VOC event :  
1.Only  oral pain medication is required.
2.
Acute complications related to VOC (such as ACS, stroke, priapi[INVESTIGATOR_8801]) have resolved to 
the extent that management can be in an outpatient setting, if applicable .
3.IV opi[INVESTIGATOR_8835] .
4.IV hydration has been discontinued, if applicable .
5.IV antibiotics have been discontinued, if applicable .
6.RBC t ransfusion is no longer required for the treatment of this VOC ,if applicable .
Refer to the current version of the Readiness -for Discharge Assessments guidance document 
for examples and further information.   
All criteria will be assessed by a member of the study  site staff who will complete the 
readiness -for-discharge questionnaire 
in the eClinRO web-based data capture s ystem,and
enter data in the eCRF s (as appropriate ). Once criteria 1 and/or2are met, they  must be 
confirmed b y the Investigator or qualified designee in the eClinRO web-based data capture
system .  The Investigator or qualified designee should be deemed , according to the 
institution’s standard of care, appropriatel y qualified to determine discharge readiness and 
could be a physician, nurse practitioner, phy sician ass istant , or other medical personnel.  To 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 66clarify , ifcriteria 1and/or 2are determined to be met by a member of the study  site staff 
other than the Investigator or qualified designee, then the Investi gator or qualified designee 
must confirm that assessment in the eClinRO web-based data capture system prior to the time 
the next scheduled assessment is to be made, or the time the subject is discharged, whichever 
comes first .  Confirmatio
n in the eClinRO web-based data capture s ystemwill also be 
required if there is a reversal in subsequent assessments of criteria 1or2.  The Investigator or 
qualified designee will be notified in real -time via the eClinRO sy stem when ever criteria 
3throu
gh6 are noted to have been metby [CONTACT_8877] .  Site -staff will ensure 
that relevant data corresponding to criteria [ADDRESS_8148]’s medical records.
The readiness
-for-discharge criteria will be assessed in all subjects at pre -defined intervals 
(and ad hoc as necessary ) from the start time of the loading dose until discharge.  Routine 
assessments are to be performed during “ daytime hours” only  (defined as 6 :01am to 
10:00 pm).  Assessments are not to be performed during “ night -time hours” (defined as 
10:01 pm to 6 :00am), unless it becomes apparent that thesubject has become 
ready
-for-discharge during the “ night -time hours”, in which case an ad hoc assessment 
should be under taken.  If all readiness- for-discharge criteria are confirmed to be met prior to 
the discharge order being issued, and there are no reversals of thereadiness -for-discharge 
status, further evaluations are no t required to be documented in the eClinRO sy stem
following the time of the discharge order.  However, a
ll subjects should be followed until 
they have left the hospi[INVESTIGATOR_307] (i.e., even after the discharge order is issued) to ensure there are no 
subsequent updates required to the readiness- for-discharge evalu ation in the eClinRO sy stem .
The schedule of readiness- for-discharge assessments may be different for the day  the study  
drug loading dose is administered than for subsequent day s.  The details around the 
difference in these schedules are as follows: 
If asubject receives their loading dose during the “ daytime hours”, 
readiness -for-discharge assessments for 
that day will be performed every  4 (±1) hours 
from the start time of the loading dose until 10 :00pm.  At 10:00 pm (±1 hour) an 
assessment will be perfor med, signaling the end of the “ daytime hours” and the start 
of the “ night -time hours”.  The next routine assessment will then be at 6 :01am (±1 
hour) the following morning, signaling the start of the “ daytime hours” for that day .  
The schedule will then be reset such that, further assessments will be performed at 4 
(±1) hourl y intervals until 10 :00pm (±1 hour) that night and this schedule of 
assessments (6:01 am, 10:00 am, 2:00 pm, 6 :00pm and 10 :00pm, each ±1 hour) will 
continue for all subsequent day sof Visit 1, until the subject is discharged from the 
hospi[INVESTIGATOR_307].  
If a subject receives their loading dose during the “ night -time hours” then the first 
routine assessment of readiness
-for-discharge will be at 6 :01am (±1 hour) at the end 
of the “ night -time hours” and the start of the “ daytime hours”.  Further assessments 
will then be performed at 4 (±1) hourl y intervals until 10 :00pm (±1 hour) that night 
and this schedule of assessments (6
:01am, 10:00 am, 2:00 pm, 6 :00pm and 10 :00pm, 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 67each ±1 hour) will continue for all subsequent days of Visit 1, until the subject is 
discharged from the hospi[INVESTIGATOR_307].   
In addition, an assessment should alway s be made at the time the decision is made to 
discharge the subject, regardless of the hour. 
If the subject is asleep during “ daytime hours” and IV opi[INVESTIGATOR_8836], the subject does not have to be woken to perform the assessment as this can be 
undertaken while the subject remains asleep.  However, if IV opi[INVESTIGATOR_8837] 1 (Only  
oral pain medication is required?) .
The study  site staff , including the investigator (or qualified designee) ,will use an electronic 
device (eg, smart phone, tablet, or computer) to access the eCli nRO web - based data capture 
system torecord and confirm responses to the criteria in the readiness- for-discharge 
questi onnaire .Example s creen shots of the readiness -for-discharge questionnaire are 
included in the eClinRO reference document.  
If the stud y site staff attempts, but is unable to complete the readiness -for discharge 
questionnaire in the eClinRO sy stem, a back
-up data capture method will be utilized as 
outlined in the Readiness -for-Discharge Assessments guidance document.
If a sub ject did not receive any  IV hydration, IV antibiotics or RBC transfusions , or had no 
acute complications related to VOC, then these criteria will not affect the   determination of 
the primary  endpoint ( ie, they are 
not applicable).
The derivation of the pri mary  endpoint of time to readiness- for-discharge makes use of the 
dates and times when each of the individual criteri aare met. In this derivation:
For criteria [ADDRESS_8149] date and time of “y es” reported by  [CONTACT_8878] “no” response recorded inthe 
eClinRO web-based data capture s ystemwill be used .
For criteria [ADDRESS_8150] date and time of “y es” reported by  [CONTACT_8879] “no” response, 
or a confirmed 
“not applicable” response ,in the eClinRO web-based data capture s ystem will be 
used.
For criteria [ADDRESS_8151] of the dates and times among the 
applicable criter ia.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

P F -0 6 4 6 0 0 3 1 
B 5 2 0 1 0 0 2 
Fi nal Pr ot oc ol A me n d me nt 3, 0 1 A pril 2 0 1 9 
Pa ge 7 1 7. 2. 1. P h ysic al E x a mi n ati o n 
A c o m plete p h ys ical e x a mi nati o n will be perf or me d at t he V O C/ Treat me nt -Rea d y Scree ni n g 
visit (see Ta ble 1, Sc he d ule of Acti vities ).  T he f oll o wi n g para meters a n d b o d y  s ys te ms will 
be assesse d a n d a n y a b n or malities descri be d: ge neral a p peara nce, s ki n, hea d, ears, e y es, n ose, 
m o ut h, t hr oat, s pi [INVESTIGATOR_050], nec k, t h y r oi d, c hest, res pi[INVESTIGATOR_1305] y ,car di o vasc ular , a b d o mi nal ( i ncl u di n g 
li ver a n d ki d ne y s), m usc ul os keletal, e xtre mities, ne ur ol o gical, ge nit o uri nar y a n d l y m p h 
n o des.   Partic ular atte nti o n will be directe d at areas affecte d b y  pai n as well as t o t he 
res pir at or y  s ys te m f or cli nical si g ns of A C S s uc h as c hest wall pai n, tac h y p nea a n d w heezi n g 
or rales o n c hest a usc ultati o n a n d t he ge nit o uri nar y s ys te m f or cli nical si g ns of pria pis m. 
A t ar gete d p h ys ical e xa mi nati o n will be perf or me d dail y  w hile t h e s u bject is i n t he h os pi[INVESTIGATOR_307] 
t hr o u g h [ADDRESS_8152] u g (if n ot disc har ge d first) , at disc har ge, a n d at 
D a y  [ADDRESS_8153] -Disc har ge F oll o w -U p visit ( Visit 4 ) (se e Ta ble 1Sc he d ule of Acti vities ) 
assessi n g t he f oll o wi n g at a mi ni m u m : s ki n, c hest, res pi[INVESTIGATOR_1305] y, car di o vasc ular , a b d o mi nal a n d 
m usc ul os keletal e xa mi nati o ns .  Partic ular atte nti o n will be directe d at areas affecte d b y pai n.  
A d d i t i o n a l  b o d y  s y s t e m s  m a y  b e  a s s e s s e d a t  t h e  d i s c r e t i o n  o f  t h e  
i n v e s t i g a t o r . 
7. 2. 2. Vit al Si g ns 
Te m perat ure, res pi[INVESTIGATOR_1305] y  rate, p ulse, bl o o d press ure, a n d p ulse o xi me tr y will be c ollecte d 
t hr o u g h o ut t he st u d yat t he V O C/ Treat me nt -Rea d y  Scree ni n g visit , dail y  w hile t he s u bject is 
i n t he h os pi[INVESTIGATOR_307], a n d at Da y  [ADDRESS_8154] -Disc har ge F oll o w -U p visit ( Visit 4 ) (see Ta ble 1Sc he d ule 
of Acti vities) .
Te m perat ure will be c ollecte d as oral, t y m pa nic, te m p oral, or a xillar y  te m perat ure meas ure d 
i n de grees Celsi us .  Sites are e nc o ura ge d t o use t he sa me met h o d t hr o u g h o u t t he st u d y .
Bl o o d press ure s h o ul d be meas ure d i n t he s u bject’s d o mi na nt ar m a n d rec or de d t o t he nearest 
m m H g.  Sites are e nc o ura ge d t o use t he sa me ar m t hr o u g h o ut t he st u d y .  All bl o o d press ure 
s h o ul d be meas ure d c o nsiste ntl y  t hr o u g h o ut t he st u d y  wit h t he s u bject i n a s u pi [INVESTIGATOR_050] p ositi o n or 
i n a sitti n g p ositi o n, de pe n di n g o n t he s u bject ’s cli nical stat us. 
T he use of a ut o mate d de vices f or meas uri n g bl o o d press ure a n d p ulse rate are acce pta ble, 
alt h o u g h, w he n d o ne ma n uall y , p ulse rate will be meas ure d i n t he b rac hial/ra dial arter y  f or at 
least [ADDRESS_8155] is l y i n g d o w n. 
P ulse o xi me tr y  will be meas ure d wit h a p ulse o xi me ter a n d re p orte d as a perce nt ( use of 
o x y ge n s u p ple me ntati o n will als o be rec or de d) . 0 9 0 1 7 7 e 1 9 1 5 d a 0 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 6- J ul- 2 0 1 9 1 8: 4 4 ( G M T) 
P F -[ADDRESS_8156] u d y  visit (see Ta ble 1, Sc he d ule 
of Acti vities) .  U nsc he d ule d cli nical la bs ma y  be o btai ne d at a n y ti me d uri n g t he st u d y t o 
assess a n y percei ve d safet y  c o ncer ns or i n acc or da nce wit h t he g ui deli nes f or s u bject safe t y  
m o nit ori n g a n d disc o nti n uati o n.  Cli nicall y  si g nifica nt a b n or mal fi n di n gs s h o ul d be rec or de d 
as A Es per Secti o n 8. [ADDRESS_8157] u d y at t he 
V O C/ Treat me nt -Rea d y  Scree ni n g visit, E n d of Treat me nt, a n d t he Da y  [ADDRESS_8158] -Disc har ge 
F oll o w -Up visit :
T a ble 3. Cli nic al L a b or at or y E v al u ati o ns –L oc al L a b or at or y 
H e m at ol o g y 
   H e m o gl o bi n    Retic ul oc yte c o u nt 
   H e m at ocrit    Platelet c o u nt 
   Re d bl o o d cell ( R B C )c o u nt    W B C c o u nt wit h differe ntial 
Ser u m C he mistr y 
   B l o o d  u r e a  n i t r o g e n ( B U N )    A l a n i n e  a m i n o t r a n s f e r a s e ( A L T / S G P T ) 
   C r e a t i n i n e    A s p a r t a t e  a m i n o t r a n s f e r a s e ( A S T / S G O T ) 
   E l e c t r o l y t e s  (S o di u m, P otassi u m, C hl ori de 
a n d    
       Bicar b o nate) w i t h  g l u c o s e    F r a c t i o n a t e d  b i l i r u b i n 
   L a c t a t e  d e h y d r o g e n a s e  ( L D H )    
Uri n al ysis 
   Pr otei n    Bl o o d 
   Gl uc ose    Nitrite 
   Ket o nes    L e u k o c y t e  e s t e r a s e 
Esti m ate d Gl o mer ul ar Filtr ati o n R ate (e G F R) at V O C/ Tre at m e nt -Re a d y Scree ni n g visit ( calc ulate d 
usi n g a ge a p pr o priate f or m ula i n A p pe n di x 1)
N ote: A h e m o gl o bi n electr o p h oresis sa m ple will be c ollecte d at t he V O C/ Treat me nt -Rea d y 
Scree ni n g visit a n d a nal yze d at t he ce ntral la b orat or y o nl y if t he s u bject’s dia g n osis 
(ie ,la b orat or y res ult b y he m o gl o bi n electr o p h oresis, H P L C, or ge n ot y pe a nal y sis) ca n n ot be 
s o urce d oc u me nte d .
7. 2. 4. Tri g gere d Re q uire me nts 
T his secti o n prese nts s pecific safet y  para meters of c o ncer n f or t he st u d y  dr u g t hat re q uire 
f oll o w -u p acti o n. 
T a ble 4. Tri g gere d Re q uire me nts 
C o n diti o n Acti o n 
C h a n ges i n Re n al F u ncti o n 
      If t he re peat e G F R res ult is 6 0 m L/ mi n/ 1. [ADDRESS_8159] o me (Secti o n 7. 2. 4. 2. 1 ) St o p st u d y dr u g a d mi nistrati o n 
Se vere C ut a ne o us M a nifest ati o ns (Secti o n 7. 2. 4. 3. 1 ) St o p st u d y dr u g a d mi nistrati o n 0 9 0 1 7 7 e 1 9 1 5 d a 0 1 b\ A p pr o v e d\ A p pr o v e d O n: 1 6- J ul- 2 0 1 9 1 8: 4 4 ( G M T) 
PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page [IP_ADDRESS]. Changes in Renal Function
The identification of deteriorating renal function could be based on rising serum creatinine or 
blood urea nitrogen ( BUN ), worsening proteinuria, or other abnormalities on urinaly sis(with 
or without microscopic evaluation) , or a change in clinical features (such as 
changes in urine 
output or phy sical findings such as pedal edema ).  Based on the clinical judgment of the 
invest igator if an y of these or other clinical features develop, the eGFR is to be repeated
(refer to Appendix 1for calculation) .  Given that subjects areeligible to participate in this 
study if their eGFR 
is >60mL/min/1.73 m2, if the repeat eGFR is 
60mL/min/1.73 m2treatment is to be stopped.
[IP_ADDRESS]. Acute Chest Syndrome Events
For the purposes of this protocol, ACS will be defined by  [CONTACT_8880]24,25as 
follows:
New pulmonary  infiltrate involving at least one complete lung segment consistent 
with the presence of alveolar consolidation, ( excluding atelectasis )AND one or more 
of the follow ing:
a.Chest pain;
b.Temperature >38.5
C;
c.Tach ypnea ;
d.Wheezing or rales ;
e.Cough .
Note: the clinical signs and sy mptoms of ACS were updated in the NIH Evidence -Based 
Management of Sickle cell Disease: Expert Panel Report (2014) , however, for the purposes 
of this protocol the above definition will continue to beused29  
Subjects will be monitored for development of ACS throughout the study .  The identification 
of ACS will be made by  [CONTACT_8881].  Clinical 
events that might represent ACS may be identified by  [CONTACT_8882].  The [COMPANY_007] study  team will notify  the study  site staff i f they  identify  a
potential
ACS event that has not been reported by [CONTACT_779].   All reported cases of potential 
ACS that occur from the time of the subject’s first dose of study  drug through the
subject’s
last visit will be evaluated by  [CONTACT_8883] y Endpoint Adjudication 
Committee (ACS -SEAC; see Section 9.7.1).
The [COMPANY_007] Study  Team or designee will provide a listing of specific documents needed to 
support ACS event adjudication by  [CONTACT_8884] -
SEAC.  Obtaining the documentation will be the 
responsibil ity of the study  site staff.  ACS event documentation will include, but is not 
limited to any  of the following: dail y hospi[INVESTIGATOR_307]/clinic notes and ph ysical examination 
documentation, hospi[INVESTIGATOR_8838], operative and procedural reports, chest x -rays, 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 74vital signs including oximetry , laboratory  reports and results of other diagnostic tests, 
autopsy  reports and death certificate information.
[IP_ADDRESS].1. Severe ACS (Withdraw from Study Drug Administration) 
For the purposes of this protocol, severe acute chest sy ndrome is defined as an ACS 
diagnosis as above ( Section [IP_ADDRESS]), and the require ment for at least one of the following:
ICU Transfer ;
Mechanical ventilation
;
Oxygen requirement of >50% FiO 2, or the use of high flow ox ygen delivery system, 
or bilevel posi tive airway pressure (BiPAP )or continuous positive airway  pressure
(CPAP ).
Subjects that develop severe ACS are to be terminated from stud y drug administration.  
Subjects that develop mild or moderate cases of ACS may  continue to receive treatment with 
study  drug.
[IP_ADDRESS]. Cutaneous Manifestations
The identification of cutaneous manifestations and acute skin rashes will be made by  [CONTACT_8885].  Clinical events of cutaneous 
manifestations and/or acute skin rashes may also be identified by  [CONTACT_8886].  The [COMPANY_007] study team will notify  the study  site staff if 
they identify  apotential event that has not been reported by [CONTACT_8887].  All cases of 
cutaneous manifestations and acute skin rashes that develop from the time of the subject’s 
first dose of study  drug through the subject’s last visit will be independently eva luated b y the 
Cutaneous Manifestations Safety  Endpoint Adjudication Committee ( CM-SEAC ; see Section 
9.7.2) to determi ne if they  constitute severe and/or generalized cutaneous events. 
A dermatologic evaluation of severe and/or generalized acute skin rashes should be 
undertaken locally .  Evaluation of 
less severe cases should also be undertaken where feasible.  
A biopsy  should be considered based upon th isdermatolog icevaluation. For severe and/or 
generalized cutaneous reactions and anyreactions that are considered “unexpected” or 
unusual, p
hotographs should be obtained per instructions provided in a separate stud y man ual
anddifferential blood count and serum aminotransferase assay sperformed .   Photographs 
and blood samples are strongl
yencouraged at the time of the event in cases of mild or 
transient cutaneous manifestations ( eg, mild and transient allergic reactions or exacerbation 
of pr e-existing conditions such as eczema).
The [COMPANY_007] Study  Team or designee will provide a list of specific documents needed to 
support rash adjudication by  [CONTACT_8888] -SEAC.  Obtaining the documentation will be the 
responsibility  of the study  site staff.  Rash event documentation will include, but is not 
limited to any  of the following: photographs, hospi[INVESTIGATOR_8839], operative reports, pathology reports of biopsy  (if 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 82serious adverse event ( SAE ) requiring immediate notification to [COMPANY_007] or its designa ted 
representative.  For all AEs, sufficient information should be obtained by  [CONTACT_8889].  The investigator is required to assess causality .  
Follow -up by  [CONTACT_8890] s equelae resolve or 
stabilize at a level acceptable to the investigator, and [COMPANY_007] concurs with that assessment.
As part of ongoing safet y reviews conducted b y the Sponsor, an y non -serious adverse event 
that is determined by [CONTACT_8891] b y the Sponsor as a n SAE .  
To assist in the determination of case seriousness further information may  be requested from 
the investigator to provide clarit y and understanding of the event in the context of the clinical 
study . 
8.2.Reporting Period
For SAE s, the active reporting period to [COMPANY_007] or its designated representative begins from 
the time that the subject or subject’s parent(s)/legal guardian/legall y acceptable 
representative provide sinformed consent /assent (either Pre -VOC/Study  Entry  cons entor 
VOC/Treatment -Ready  consent depending on the subject’s entry  point into the study ), which 
is obtained prior to the subject
’sparticipation in the study , ie, prior to undergoing an y 
study -related procedure and/or receiving study  drug , through and inc luding the subject’s last 
visit or 28calendar day s after the last administration of the study  drug , whichever is longer .  
Serious adverse events occurring to a subject after the active reporting period has ended 
should be reported to the Sponsor if the in vestigator becomes aware of them; at a minimum, 
all serious adverse events that the investigator believes have at least a reasonable possibility  
of being related to study  drug are to be reported to the Sponsor.
AEs (serious and non -serious) should be recor ded on the CRF from the time the subject has 
taken at least one dose of study  drug through the subject ’s last visit.
8.3.Definition of an Adverse Event
An AEis an y untoward medical occurrence in a clinical investigation subject administered a 
product or medical device; the event need not necessarily  have a causal relationship with the 
treatment or usage.  Examples of AEs include but are not limited to: 
Abnor mal test findings;
Clinically  significant symptoms and signs;
Changes in ph ysical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 83Additionally , they  may  include the signs or s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy (EDP) ;
Exposure via breastfeeding ;
Medication error ;
Occupational e xposure.
8.4.Medication Errors
Medication errors may  result, in this st udy, from:
Incorrect route of administration;
Administration of expi[INVESTIGATOR_8840];
Administration of the wrong product ;
Administration to the wrong subject;
Administration at the wrong time;
Administration at the wrong dosage strength;
Administration of incorrect dose of study  drug;
Administration of study  drug that has undergone temperature excursion from the 
specified storage range, unless it is determined by  [CONTACT_8892].
Such medication errors oc curring to a stud y participant are to be captured on the medication 
error CRF which is a specific version of the AE page ,and on the SAE form when 
appropriate.  In the event of medication dosing error, the sponsor should be notified 
immediately .
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 84Medication errors are reportable irrespective of the presence of an associated AE/SAE, 
including:
Medication errors involving subject exposure to the study  drug;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error iscaptured on the medication error version of the AE page
and, if applicable, an y associated adverse event(s) is captured on an AE CRF page.
8.5.Abnormal Test Findings
The criteria for determining whether an abnormal objective test finding should be reported as 
an AEare as follows: 
Test result is associated with accompan ying symptoms; and/or
Test result requires ad ditional diagnostic testing or medical/surgical intervention;
and/or
Test result leads to a change in stud y dosing or discontinuation from the study, 
significant additional concomitant drug treatment, or other therap y;and/or
Test result is considered to b e an AEby [CONTACT_8893].
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
reporting as an AE.
8.6.Serious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospi[INVESTIGATOR_1081];
Results in persistent or significant disability /incapacity (substantial disruption of the 
ability  to conduct normal life functions);
Results in congenital anomaly /birth defect.
Medical and scientific judgment isexercised in determining whether an event is an importa nt 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospi[INVESTIGATOR_059].  However, if it is determined that the event may  jeopardize 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8160] or may  require intervention to prevent one of the other AEoutcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; 
or de velopment of drug dependency  or drug abuse.
8.6.1. Protocol -Specified Serious Adverse Events 
Unless the investigator believes that there is a causal relationship between study  drug and the 
event specified below, this event should not be reported by  [CONTACT_8894] o fthis protocol.  
However, this event should still be captured as an AE in the CRF ifit meets reporting 
requirements detailed in Section 8.2.
The protocol -specified event that will not normally  be reported in an expedited manner: 
The initial, uncomplicated VOC prompting entry  into Treatment -Ready  
Screening.  
Note : If a subject si gnsPre-VOC consent and has a VOC requiring 
hospi[INVESTIGATOR_059], but does not enter intoTreatment -Ready  Screening, th e VOC isto 
be reported as an SAE.  In addition, f or allsubject s, any  re-hospi[INVESTIGATOR_8841] y follow -up period is to be reported as an SAE. 
Should an aggregate analysis indicate that these prespecified events occur more frequently  
than expected based on the expectation of frequency  of the event(s) in question in the 
population for comparison, eg, based on epi[INVESTIGATOR_8842], literature , or other data,  then 
this will be submitted and reported in accordance with [COMPANY_007]’s safet y reporting requirements.  
Aggregate anal ysis of safety  data will be performed on a regular basis per internal standard 
operating procedure s.
8.6.2. Potential Cases of Drug- Induced Liver Injury 
Abnormal values in aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 
levels concurrent with abnormal elevations in total bilirubin level that meet the criteria 
outlined below in the absence of other causes of liver injury  are considered potential cases of 
drug-induced liver injury (potential Hy ’s Law cases) and should alway s be considered 
important medical events. 
The threshold of laboratory  abnormalities for a potential case of drug -induced liver injury  
depends on the subject’s individual baseline values and underl ying conditions.   Subjects who 
present with the following laboratory  abnormalities should be evaluated further to 
definitively  determine the etiology  of the abnormal labora tory values:
Subjects with AST or ALT and total bilirubin baseline values within the normal range 
who subsequently  present with AST or AL T 3times the upper limit of normal ( ×
ULN) concurrent with a total bilirubin 2
×ULN with no evidence of hemoly sis and 
an alkaline phosphatase 2 × ULN or not available;
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 86For subjects with preexisting ALT OR AST OR total bilirubin values above the 
ULN , the following threshold values should be used in the definition mentioned 
above:
For subjects with pre -
existing AST or ALT baseline values above the normal 
range: AST or ALT values  2times the baseline values and 3 ×ULN, or 
8 ×ULN (whichever is smaller).
Concurrent with :
For subjects with pre -existing values of total bilirubin above the normal range: 
Total bilirubin level increased from baseline by  [CONTACT_8895] 1 × ULN or
if the value reaches ≥3×ULN (whichever is smaller).
The subject should return to the investigational site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_8161] bilirubin, gamma- glutamy l 
transferase, prothrombin time (PT)/ international normalized ratio ( INR), and alkaline 
phosphatase.  A detailed history , including relevant information, such as review of ethanol, 
acetaminophen , recreational drug ,and sup
plement consumption, family  history , occupational 
exposure, sexual history , travel history , history  of contact [CONTACT_4490] a jaundiced person , surgery , 
blood transfusion, history of liver or allergic disease, and work exposure, should be collected.  
Further testi ng for acute hepatitis A, B, or C infection and liver imaging ( eg, biliary  tract) 
may be warranted.   
All cases confirmed on repeat testing as meeting the laboratory  criteria 
defined above , with no other cause for liver function test ( LFT)
abnormalities ide ntified at 
the time should be considered potential Hy ’s Law cases irrespective of availability  of all the 
results of the investigations performed to determine etiology  of the abnormal LFTs.  Such 
potential Hy ’s Law cases should be reported as SAEs.
8.7.Hospi[INVESTIGATOR_4589] (even less than 24 hours) in a hospi[INVESTIGATOR_8843].  Admission also 
includes transfer within the hospi[INVESTIGATOR_4591]/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospi[INVESTIGATOR_059]; 
however, the event leading to th e emergency  room visit should be assessed for medical 
importance.
Hospi[INVESTIGATOR_4592]:
Rehabilitation facilities;
Hospi[INVESTIGATOR_4593];
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 87Respi[INVESTIGATOR_4594] ( eg,caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same day  surgeries (as outpatient/same day /ambulatory  procedures).
Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_2505], 
clinical AEis not in itself a nSAE .  Examples include: 
Admission for treatment of a preexisting condition not associated with the 
development of a new AEor with a worsening of the preexisting condition ( eg, for 
work -
up of persistent pre- treatment lab abnormality);
Social admission ( eg,subject has no place to sleep);
Administrative admission ( eg,for yearly physical exam);
Protocol -specified admission during a stud y (eg,for a procedure required by  [CONTACT_8896]);
Optional admission not associated with a precipi[INVESTIGATOR_4596](eg,for elective 
cosmeti c surgery );
Hospi[INVESTIGATOR_4597] a medical AE;
Pre-planned treatments or surgical procedures .  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject .
Diagnostic and therapeutic non- invasive and invasive procedures, such as surgery , should not 
be reported as 
AEs.  However, the medical condition for which the procedure was performed 
should be reported if it meets the definition of an AE.  For example, an acute appendicitis 
that begins during the AEreporting period should be reported as the AE, and the resulting 
appendectomy  should be recorded as treatment of the AE.
8.8.Severity Assessment
If required on the AECRFs , the investigator will use the adjectives M ILD, MODERATE, 
or SEVERE to des cribe the maximum intensity  of the AE.  For purposes of consistency , 
these intensity  grades are defined as follows:
MILD Does not interfere with subject's usual function.
MODERATE Interferes to some extent with subject's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE .  For example, a headache may  be severe (interferes significantly  with 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8162]'s usu al function) but would not be classified as serious unless it met one of the 
criteria for SAE s, listed above.
8.9.Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
non-serious); the investigator must record the causal relationship in the CRF, as appropriate, 
and report such an assessment in accordance with the serious adverse reporting requirements 
if applicable.  An investigator’s causality  assessment is the determination of whether there 
exists a reasona ble possibility  that the study  drug caused or contributed to an AE; generall y 
the facts (evidence) or arguments to suggest a causal relationship should be provided .  If the 
investigator does not know whether or not the 
study  drug caused the event, then the event 
will be handled as “related to study  drug ” for reporting purposes, as defined by  [CONTACT_1034] 
(see the Section on Reporting Requirements ).  If t he investigator's causality  assessment is 
"unknown but not related to study  drug ", this should be clearl y documented on study  records. 
In addition, if the investigator determines an SAE is associated with study  procedures, the 
investigator must record thi s causal relationship in the source documents and CRF, as 
appropriate, and report such an assessment in accordance with the SAE reporting 
requirements, if applicable.
8.10. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed produc ts, an exposure during 
pregnancy  (EDP ) occurs if:
1. A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg , because of treatment or environmental exposure) to the study  drug; or 
the female becomes or is found to be pregnant after discontinuing and/or being 
exposed to the study  drug; 
An example of environmental exposure would be a case involving direct contact [CONTACT_4490] 
a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
2. A male has been exposed ( eg, because of treatment or environmental exposure) to the 
study  drug prior to or around the t ime of conception and/or is exposed during his 
partner’s pregnancy .
If astudy  subject or study  subject’s partner becomes or is found to be pregnant during the 
study  subject’s treatment with the study  drug , the investigator must submit this information 
to the [COMPANY_007] Drug Safet y Unit on a n SAE report f orm and an EDP supplemental form, 
regardless of whether an SAE has occurred .  In addition, the investigator must submit 
information regarding environmental exposure to a [COMPANY_007] product in a pregnant woman ( eg, a 
subject 
reports that she is pregnant and has been exposed to a cy totoxic product by  [CONTACT_8897][INVESTIGATOR_4598]) using the EDP supplemental form.  This must be done irrespective of whether an 
AEhas occurred and within 24 hours of awareness of the exposure. The information 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 89submitted should include the anticipated date of delivery  (see below for information related 
to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unk nown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] of the outcome as a follow up 
to the initial EDP s upplemental f orm.  In the case of a live birth, the structural integrity  of the 
neonate can be assessed at the time of birth.  In the event of a termination, the reason(s) for 
termination should be specified and, if clinicall y possible, the structural integrit y of the 
terminated fetus should be assessed b y gross visual inspection (unless pre -procedure test 
findings are conclusive for a congenital anomal y and the findings are reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, o r congenital anomal y [in a 
live–born baby , a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported as SAE s follows: 
Spontaneous abortion includes miscarriage and missed abortion ;
Neonatal deaths that occur within [ADDRESS_8163] 
to causality , as SAE s.  In addition, infant deaths after 1 month should be reported as 
serious adverse events when the investigator assesses the infant death as related or 
possibly  related to exposure to the study  drug .
Additional information regarding the EDP may be requested by  [CONTACT_093].  Further 
follow -up of birth outcomes will be handled on a case -by-case basis ( eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the study  subject with the Pregnant Partner Release of Information 
Form to deliver to his partner . The Investigator must document in the source documents that 
the subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.11. Occupational Exposure
An occupational exposure occurs when ,during the performance of job dutie s, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to the drug safet y unit within 24 hours of the 
Investigator’s awareness, using the SAE report form, regardless of whether there is an 
associated AE/SAE.  Since the information does not pertain to a subject enrolled in the study , 
the information is not reported on a CRF, however a cop y of the completed SAE r eport form 
is maintained in the investigator site file.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 908.12. Withdrawal Due to Adverse Events (See Also the Section on Subject Withdrawal )
Withdrawal d ue to AE s should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted earlier, and recorded on the appropriate AE CRF 
page.
When a subject withdraws because of anSAE , the SAE must be reported in accordance with 
the reporting requirements defined below.
8.13. Eliciting Adverse Event Information
The investigator is to report all directly  observed AEs and all AEs spontaneously  reported b y 
the study  subject /parent (s)/legal guardian/ legally  acceptable representative .  In addition, each 
study  subject /parent (s)/legal guardian/legall y acceptable representative will be questioned 
about AEs .
8.14. Reporting Requirements
Each AEis to be assessed to determine if it meets the criteria for SAE s.  If a nSAE occurs, 
expedited reporting will follow local and international regulations, as appropriate.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8164] be made 
immediately , irrespective of the extent of av ailable AEinformation.  This timeframe also 
applies to additional new information (follow- up) on previously  forwarded SAE reports as 
well as to the initial and follow- up reporting of EDP , exposure via breastfeeding , and 
occupational exposure cases. 
In the rare event that the investigator does not become aware of the occurrence of a nSAE
immediately  (eg, if an outpatient study  subject initially  seeks treatment elsewhere), the 
investigator is to report the event within 24 hours after learning of it and docu
ment the time 
of his/her first awareness of the AE .
For all SAE s, the investigator is obligated to pursue and provide information to [COMPANY_007] in 
accordance with the timeframes for reporting specified above.  In addition, an investigator 
may be requested by  [CONTACT_4695] -up information in an 
expedited fashion.  This i nformation collected for SAE sismore detailed than that captured 
on the 
AECRF .  In general, this will include a description of the AEin sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  Information on other possible causes of the event, such as concomitant 
medications, vaccines, and/orillnesses must be provided.  I n the case of a subject d eath, a 
summary of available autopsy  findings must be submitted as soon as possible to [COMPANY_007] or its 
designated representative. 
8.14.2. Non-Serious Adverse Event Reporting Requirements
All AEs will be reported on the AEpage(s) of the CRF.  I t should be noted that the form for 
collection of SAE information is not the same as the AECRF.  Where the same data are 
collected, the forms must be completed in a consistent manner.  For example, the same AE
term should be used on both forms.  AEs should be reported using concise medical 
terminology  on the CRFs as well as on the form for collection of SAE information.
8.14.3. Sponsor ’sReporting Requirements to Regulatory Authorities
Adverse event reporting, including suspected unexpected serious adverse reactions, will be 
carried out in accordance with applicable local regulations.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 949.2.1. Analysis of Primary Endpoint 
The primary  endpoint is time to readiness- for-discharge from the hospi[INVESTIGATOR_307].  Time to 
readiness -for-discharge is defined as the difference between the readiness- for-discharge date 
and time (see Section 7.1.1 for detail) and the start date and time of the first infusion of study  
drug in hours. 
Below are examples of scenarios where subjects receive an infusion of study  drug but do not 
meet the primary  endpoint criteria: 
If one or more applicable criteria are not met for a subject before the subject is 
discharged or are missing, then the time to readiness- for-discharge will be treated as 
censored .  Ifa subject dies in the hospi[INVESTIGATOR_8844], the n the time to 
readiness -for-discharge will be tr eated as censored.
If a subject is not hospi[INVESTIGATOR_8845] y terminates from the stud y before all 
criteria are met, the time to readiness -for-
discharge will be treated as censored.If a 
subject is randomized but not infused with study  drug, the time to 
readiness -for-discharge will be defined as the time from randomization to the time of 
the subject’s termination and will be treated as censored.
Details on censoring rules for the time to readiness- for-discharge are provided in the SAP.
The primary  analysis will be performed using the Cohort [ADDRESS_8165] where the stratification sare age group (Cohort 1 and Cohort 2 combined or 
Cohort 1 
only) and genot ype, For Cohort 2, a log- rank test stratified by  [CONTACT_8899].
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 979.4.Safety Analysis
The safet y data ( eg, AEs, SAEs, phy sical exams, laboratory  tests, vital signs) will be 
summarized in accordance with the Clinical Data Interchange Standards Consortium 
(CDI SC) and[COMPANY_007] Standards (CaPS) .  Safet y data that will be specifically summarized 
include:
Adverse events according to CaPS ;
Safety  laboratory  tests according to CaPS ;
Physical exams and vital signs assessments according to CaPS ;
Incidence of adjudicated ACS and incidence of adjudicated severe and/or generalized 
cutaneous manifestations anal yzed using 
exact methods.
Percent of subjects re -hospi[INVESTIGATOR_8846] 7, [ADDRESS_8166] beenused for the futility  decision -making   to maintain th e overall nominal 
significance level for the final 
efficacy  anal ysisat 0.05 (2-sided test).
If an interim analy sisfor futility wereconducted, the details of the objectives, decision 
criteria and method of maintaining the stud y bl
ind as per [COMPANY_007]’s SOPs w ould have been
documented and approved in a
n E-DMC charter and the detailed analysis plan documented 
and approved in a SAP.
9.6.Data Monitoring Committee 
This study  will use an External D ata Monitoring Committee (E- DMC).   The E - DMC will be 
responsible for ongoing monitoring of safet yof subjects in the study  according to the 
Charter.  The E -DMC will include members, external to the Sponsor ,with expertise in the 
clinical management of adult and pediatric SCD patients, statistic s, or clinical pharmacolog y .  
The E- DMC will receive safet y summaries and subject listings presented by [CONTACT_8900] t he option to review fully unblinded safet y data and/or 
efficacy  data if necessary .  
The E
-DMC will review accumulating data from this study  on a regular basis, at least every  
6months and particular focus will be placed upon evaluation of the pediatric sa fety data .  
The initial data review meeting will occur after the first 6 pediatric subjects (6 -11years of 
age) have completed the study , or approximately  6months after first subject first visit 
(FSFV), whichever comes first.  An additional review of subjects 6-[ADDRESS_8167] completed the study .  The sponsor and the E -DMC can 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8168] periodic monitoring visits to ensure 
that the protocol and Good Clinical Practices ( GCPs )are being followed.  The monitors may  
review source documents to confirm that the data recorded on CRFs is accu rate.  The 
investigator and institution will allow [COMPANY_007] monitors/auditors or its agents and appropriate 
regulatory  authorities direct access to source documents to perform this verification.
The study  site may  be subject to review by  [CONTACT_4707] (IRB)/ Ethics 
Committee (EC), and/or to quality  assurance audits performed b y [COMPANY_007], or companies 
working with or on behalf of [COMPANY_007], and/or to inspection by  [CONTACT_8901].
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RE CORD KEEPI[INVESTIGATOR_1645]
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole property of [COMPANY_007] and should not be made available in any form to 
third parties, except for authorized representatives of [COMPANY_007] or appropriate regulatory  
authorities, without written permission from [COMPANY_007].
The investigator has ultimate res ponsibility  for the collection and reporting of all clinical, 
safet y and laboratory data entered on the CRFs and any other data collection forms (source 
documents) and ensuring that they
 are accurate, authentic / original, attributable, complete, 
consisten t, legible, timely  (contemporaneous), enduring and available when required.  The 
CRFs must be signed b y the investigator or b y an authorized staff member to attest that the 
data contained on the CRFs is true. Any corrections to entries made in the CRFs orsource 
documents must be dated, initialed and explained (if necessary ) and should not obscure the 
original entry . 
In most cases, the source documents are the hospi[INVESTIGATOR_307]'s or the ph ysician's subject chart.  In 
these cases data collected on the CRFs must mat ch the data in those charts. 
In some cases, the CRF, or part of the CRF, may  also serve as source documents.  In these 
cases, a document should be available at the investigator’s site as well as at [COMPANY_007] and clearl y 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 101retained b y the investigator according to International Council for Harmonisation ( ICH), 
according to local regulations, or as specified in the Clinical Study  Agreement (CSA) , 
whichever is longer.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period ( eg, retirement, relocation), [COMPANY_007] should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to [COMPANY_007] , such as another 
investigator, another institution, or to an independent third part y arranged by [CONTACT_4618]. 
Investigator records must be kept for a minimum of [ADDRESS_8169] obtain [COMPANY_007]'s written permission before disposing of an y records, 
even if retention requirements have been met.
Study  sites will ret ain  eClinRO records as required under their contracts with 
[COMPANY_007] and the Investigator Initiation Package.  These records will include archives of clinical 
data and stud y documentation to be sent to them by [CONTACT_8902].  The stud y 
sites will review the contents of 
 eClinRO archives when they  are first provided by  
[CONTACT_8902].  Once the sites have determined that the archived data is 
complete and accurate, they  will send signed acknowledgement forms to the [COMPANY_007] study  
team.
[COMPANY_007] will retain records of the design, development, testing, rollout, maintenance and close 
out of eClinRO and store such records per the relevant SOPs.  [COMPANY_007] will also retain 
the acknowledgement forms sent by  [CONTACT_8903].
12.ETHICS
12.1.
Institutional Review Board (IRB)/Ethics Committee (EC)
It isthe responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent /assent documents , and other relevant documents, eg,
recruitment advertisements, if applicable, from the I RB/EC.  All correspon dence with the 
IRB/EC should be retained in the Investigator File.  Copi[INVESTIGATOR_1099]/EC approvals should be 
forwarded to [COMPANY_007].
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminat e apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and [COMPANY_007] in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with legal and regulato ry requirements, as well as 
the general principles set forth in the International Ethical Guidelines for Biomedical 
Research Involving Human Subjects (Council for International Organizations of Medical 
Sciences 2002), Guidelines for GCP (ICH 1996), and the Declaration of Helsinki (World 
Medical Association 2008). 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8170]’s actual identit y.  In case of data transfer, [COMPANY_007] will maintain high standards of 
confidentiality  and protection of subject personal data consistent with applicable privacy  
laws, and requirements of government agencies including the Centers for Medicare and 
Medicaid Services .
The informed consent /assent document smust be in compliance with ICH GCP, local 
regulatory  requir ements, and legal requirements , including applicable privacy  laws .
The informed consent /assent document s used during the informed consent process must be 
reviewed b y the sponsor, approved b y the IRB/EC before use , and available for inspection.
The invest igator must ensure that each study  subject, or his/her legal ly acceptable
representative, or parent(s) or legal guardian if a minor, is fully  informed about the nature 
and objectives of the study and possible risks associated with participation. 
Prior to any  screening procedures , at the Pre-VOC/Study  Entry  Screening and/or 
VOC/ Treatment -Ready  Screening , the study  will be thoroughly  explained to the subject’s 
parent/legall y acceptable representative and/or the subject.  If the subject wishes to 
participate in the study  and, if appropriate, the parent/legally  acceptable representative also
desires the subject to participate in the study , an IRB/EC -
approved informed consent will be 
signed and dated b y the subject or the legall y acceptable representative, befor e any screening 
procedures are performed that are specific to the study .  
Whenever consent is obtained from a subject’s legall y acceptable representative/parent(s) or 
legal guardian, the subject’s assent (affirmative agreement) must subsequently  be obtain ed 
when the subject has the capacity  to provide assent, as determined by  [CONTACT_1201]/EC.  If the 
investigator determines that a subject’s decisional capacity  is so limited he/she cannot 
reasonabl y be consulted, as permitted by [CONTACT_1201]/EC and consistent with lo cal regulatory  and 
legal requirements, then the subject’s assent may  be waived with source documentation of 
the reason assent was not obtained.  If the stud y subject does not provide his/her own 
consent, the source documents must record wh y the subject did not provide consent (eg, 
minor, decisionally  impaired adult), how the investigator determined that the person signing 
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8171]’s legally acceptable representative, the consent signer’s 
relationship to the study  subject (eg, parent, spouse) and that the subject’s assent was 
obtained, or waived.  If assent is obtained verball y it must be documented in the source 
documents. The signed documents will be retained at the site and the investigator must 
document in the source documents that informed consent and assent were obtained. 
The Investigator will need to make the determination as to whether or not the potential 
subject re ceiving IV opi[INVESTIGATOR_8847].  If not, the subject will need a legal ly acceptable representative to consent on the 
subject’s behalf.  The determination of capacit y to consent should be documented in the 
source records.
In determining which potential subjects are capable of providing assent, the I nvestigator 
and/or IRB/EC should take into account the age, maturity , and ps ychological state of the 
potential subjects. The American Academy  of Pediatrics advises that assent usually  should 
be obtained from all subjects with an intellectual age of [ADDRESS_8172] be re -consented as adults to remain in the 
study .  If the enrollment of ‘emancipated minors’ is permitted by  [CONTACT_1758] , the IRB/EC, and 
local law, they
 must provide documentation of legal status to give consent without the 
permission of a parent or legal guardian.
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject or the subject's legal ly acceptable representative , parent(s) or legal 
guardian and the subject’s assent, when applicable, before an y stud y-specific activity  is 
performed , unless a waiver of informed consent has been granted by  [CONTACT_2717]/EC . The 
investigator will retain the original of each subje ct's signed consent /assent document .
12.4. Subject Recruitment
Advertisements and patient-centric engagement tools and activities approved by  [CONTACT_8904] .  To facilitate 
possible logistical burdens for subjects, transportation services will be made available to 
subjects to and from study visits.
12.5. Reporting of Safety Issues and S erious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed ( ie,clinical hold) by [CONTACT_8905], or if the investigator is aware of any  new 
information which might influence the evaluation of the benefits and risks of the study  drug , 
[COMPANY_007] should be informed immediately . 
In addition, the investigator will inform [COMPANY_007] immediately of an y urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-[ADDRESS_8173] Visit. 
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opi[INVESTIGATOR_1100]/EC, drug safety  problems, or at the discretion of [COMPANY_007].  I n 
addition, [COMPANY_007] retains the right to discontinue development of rivipansel at any  time.
If a stud y is prematurel y terminated or discontinued, [COMPANY_007] will promptly  notify  the 
investigator.  After notification, the investigator must contact [CONTACT_8906][INVESTIGATOR_4601]  (if applicable) within 1week .  As dir ected b y [COMPANY_007], all study  
materials must be collected and all CRFs completed to the greatest extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by [CONTACT_8907] h posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov) , the European Clinical Trials 
Database (EudraCT), and/or 
www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.  
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007] -sponsored 
interventional studies conducted in patients that evaluate the safet y and/or efficacy of a [COMPANY_007] 
product , regardless of the geographical location in which the study is conducted.  US Basic 
Results are submitted for posting within [ADDRESS_8174]
[COMPANY_007] posts European Union ( EU)Basic Results on EudraCT for all [COMPANY_007] -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the primary completion date for studies in adult populations or 
within 6 months of the pr imary  completion date for studies in pediatric populations.
www.pfizer.com
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 105[COMPANY_007] posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov .
15.2. Publications by [CONTACT_8908] y information collected or 
generated b y Investigator s, whether or not the results are favorable to the Investigational 
Drug. However, to ensure against inadvertent disclosure of Confidential Information or 
unprotected Inventions, Investigator swill provide [COMPANY_007] an opportunity  to review an y 
proposed publication or other ty pe of disclosure before it is submitted or otherwise disclosed.
Investigator swill provide manuscripts, abstracts, or the full text of any  other intended 
disclosure (poster present ation, invited speaker or guest lecturer presentation, etc.) to [COMPANY_007] 
at least [ADDRESS_8175], remove an y previously undisclosed Confidential I nformation 
(other than the Stud y results themselves) before disclosure.
If the Study  is part of a multi -cente r study , Investigators agree that the first publication is to 
be a joint publication covering all centers. However, if a joint manuscript has not been 
submitted for publication within [ADDRESS_8176] to the other 
requirements of this Section.
For all publications relating to the Study , Institution swill comply  with recognized ethical 
standards concerning publications and authorship, includi ng Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  [CONTACT_8909] l Journal Editors.
Publication of study  results is also provided for in the Clinical Study  Agreement between 
[COMPANY_007] and the institution.  I n this section entitled Publications by  [CONTACT_4718], the defined 
terms shall have the meanings given to them in the Clinical Study  Agreement.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page [ZIP_CODE].REFERENCES
1. Centers for Disease Control and Prevention S ickle Cell D isease homepage . Available 
at: http://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed February 12, 2014.  
2.
Davis H, Roscoe M, Moore J, et al. Cost of hospi[INVESTIGATOR_8848]. Public Health Rep . 1997;112:40-3.
3. Stuart MJ, Nagel RL . Sickle -cell disease. Lancet . 2004;364:1343 -60.
4. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future 
promise. J Clin I nvest . 2007;117:850 -8.
5. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk 
factors. N Engl J Med. 1991;325:11-6.
6. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340:1021-30.
7. American Academy  of Pediatrics, Section on Hematology /Oncology  and Committee on 
Genetics. Health supervision for children with sickle cell diseas e. Pediatrics . 
2002;109:526-35.
8. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am . 
2005;19:785 -802.
9. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease --Life 
expectancy  and risk factors for earl y death. N Engl J Med. 1994;330(23):1639 -44.
10. Smith WR, Penberthy  LT, Bovbjerg VE, et al. Daily  assessment of pain in adults with 
sickle cell disease. Ann Intern Med . 2008;148(2):94-101.
11. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 
1997; 337:762-9.
12. Okpala I. Leukocy te adhesion and the pathophy siology  of sickle cell disease. Curr Opin 
Hematol . 2006;13:40-4.
13. Blum A, Yeganeh S, Peleg A, et al. Endothelial function in patients with sickle cell 
anemia during and after sickle cell crises. J Thro mb Thromboly sis. 2005;19(2):83 -6.
14. Kato GJ, Marty r S, Blackwelder WC, et al. Levels of soluble endothelium- derived 
adhesion molecules in patients with sickle cell disease are associated with pulmonary  
hypertension, organ d ysfunction, and mortality . Br J Hae matol . 2005;130:943-53.
15. Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sickle 
cell vascular occlusion: A new paradigm. Proc Natl Acad Sci . 2002;99:3047-51.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page [ZIP_CODE]. Kaul DK , Hebbel RP. Hypoxia/reoxy genation causes inflammatory  response in 
transgenic sickle mice but not in normal mice. J Clin I nvest . 2000;106(3):411-20.
17. Tedder TF, Steeber DA, Chen A, et al. The selectins: vascular adhesion molecules. Br J 
Rheumatol . 1995;34:1 101-4.
18. Ebnet K, Vestweber D. Molecular mechanisms that control leukocy te extravasation: 
The selectins and chemokines. Histochem Cell Biol . 1999;112:1 -23.
19. Chen S, Springer TA. Selectin receptor -ligand bonds: Formation limited by  [CONTACT_8910]. Proc Natl Acad Sci . 2001;98:950 -5.
20. Blann AD, Nadar SK, L ip GYH. The adhesion molecule P- selectin and cardiovascular 
disease. Eur Heart J . 2003;24:2166-79.
21. Kansas GS. Selectins and their L igands: Current concepts and controversie s. Blood . 
1996;88: 3259-87.
22. Embury  SH, Matsui NM, Ramanujam S, et al. The contribution of endothelial cell 
P-selectin to the microvascular flow of mouse sickle ery throcy tes in vivo. Blood . 
2004;104(10):[ADDRESS_8177], reverses 
acute vascular occlusions in sickle cell mice.  Blood. 2010; 116: [ADDRESS_8178] 
syndrome in sickle cell disease. N Engl J Med. 2000; 342:1855-1865.
25. National Institutes of Health; Division of Blood Diseases and Resources. The 
management of sickle cell disease. 4th ed. NIH Publication No. 02 -2117. Bethesda, 
MD: US Department of Health and Human Services; 2002.
26. Farrar JT, Young JP Jr, LaMoreaux L , et al. Clinical importance of changes in chronic 
pain intensity  measured on an 11 -point numerical pain rating scale. Pain. 2001 
Nov;94(2):149 -58.
27. Wong -Baker Faces Foundation homepage. Available at: http://wongbakerfaces.org/.  
Accessed Februar y 25, 2015 .
28. Cleeland CS. Pain assessment in cancer. In: Osaba D(ed). Effect of Cancer on Quality 
of Life, Chapter 21. CRC Press, Boca Raton FL, 1991.
29. National Institutes of Health. Evidence -Based Management of Sickle Cell Disease: 
Expert Panel Report.  Bethesda, MD: US Department of Health and Human Services; 
2014.  Available at: www.nhlbi.nih.gov/guidelines.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page [ZIP_CODE]. Hackshaw A: A Concise Guide to Clinical Trials, 29 APR 2009; Wiley  Online L ibrary .  
Available at: 
http://onlinelibrary .wiley.com.proxy 1.athensams.net/doi/10.1002/9781444311723.oth2/
pdf
31. Levey  AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A 
new equation to estimate glomerular filtration rate. Ann Intern Med. 
2009;1 50(9):604-12
32. Schwartz GJ, et al. New equations to estimate GFR in children with CKD. J Am Soc 
Nephrol. 2009; 20: 629 -637.
33. Schwartz GJ and Work DF. Measurement and estimation of GFR in children and 
adolescents. Clin J Am Soc Nephrol. 2009; 4 (11): 1832-43.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 109Appendix 1.Estimated Glomerular Filtration Rate (eGFR) Calculations
Calculation for subjects 18 years of age :
The Chronic Kidney  Disease Epi[INVESTIGATOR_8849] (CKD- EPI) equation estimate s
glomerular filtration rate (GFR) from serum creatinine, age, sex, and race for adults age d
≥ 18 years.31
CKD -EPI [INVESTIGATOR_8850]
A CKD -EPI [INVESTIGATOR_8851]/or site staff is provided via the study -
specific Firecrest web -portal.
  Calculation for subjects < 18 years of age :
Bedside Schwartz Equation32,33
eGFR = 0.413 x (Height in cm) / (Serum Creatinine in mg/dl)
ABedside Schwartz Calculator for investigator and/or site staff is provided via the 
study -specific Firecrest web -portal.
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 114
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)

PF-06460031
B5201002
Final Protocol Amendment 3,01 April 2019
Page 117
090177e1915da01b\Approved\Approved On: 16-Jul-2019 18:44 (GMT)
